| Excerpt | Reference |
|---|
| "Diabetic nephropathy is a dangerous and insidious complication of diabetes mellitus." | ( Scheler, F, 1977) |
| "The diabetic nephropathy is the cause of the secondary arterial hypertension." | ( Bottermann, P; Classen, M, 1991) |
| "Diabetic nephropathy is the most frequent cause of chronic renal insufficiency in adults." | ( Kolousková, S; Lebl, J; Snajderová, M, 1991) |
| "Diabetic nephropathy is the dominant cause of hypertension in insulin-dependent diabetics, and long-term rigid antihypertensive treatment inhibits the progression of nephropathy, probably even when there is renal insufficiency." | ( Conde, N; Gums, G; Heinke, P; Schulz, B; Strese, J; Zander, E; Zander, G, 1990) |
| "Diabetic nephropathy is a major cause of the increased morbidity and mortality in insulin-dependent diabetes mellitus." | ( Ayo, SH; Garoni, JA; Glass, WF; Kreisberg, JI; Radnik, RA, 1990) |
| "Incipient diabetic nephropathy is defined as persistently elevated UAE (greater than 15 micrograms/min), but no clinical proteinuria." | ( Christensen, CK; Mogensen, CE, 1986) |
| "Only in the case of diabetic nephropathy is there yet reasonable evidence of antihypertensive treatment reducing the rate of progression of the disease." | ( Drury, PL, 1983) |
| "Detection of early diabetic nephropathy is necessary to postpone or even prevent progression of irreversible kidney damage by therapeutic measures." | ( Füessl, HS; Goebel, FD; Schmeidl, T; Vogel, S, 1983) |
| "Progression of diabetic nephropathy is now associated with intrarenal hemodynamic disorders (renal hyperperfusion, hyperfiltration, intraglomerular hypertension)." | ( Belushkina, NN; Dedov, II; Ragozin, AK; Riaposova, IK; Severina, IS; Shestakova, MV, 1995) |
| "Progression in diabetic nephropathy is usually determined by repeated measurements of glomerular filtration rate and expressed as rate of decline in glomerular filtration rate." | ( Astrup, AS; Parving, HH; Rossing, P; Smidt, UM, 1994) |
| "Diabetic nephropathy is the main cause of increased mortality and morbidity in IDDM patients." | ( Hommel, E; Parving, HH; Rossing, P; Smidt, UM, 1994) |
| "Diabetic nephropathy is characterized by hypertension and a relentless decline in kidney function." | ( Gall, MA; Nielsen, FS; Parving, HH; Rossing, P; Skøtt, P; Smidt, UM, 1994) |
| "Diabetic nephropathy is characterized by albuminuria which proceeds to overt proteinuria." | ( Assmann, KJ; Berden, JH; Bruijn, JA; Hermans, J; Schrama, E; Tamsma, JT; van den Born, J; Veerkamp, JH; Weening, JJ; Wieslander, J, 1994) |
| "1." | ( Bell, GM; Mason, H; McClelland, P; Patrick, AW; Stevenson, A; White, MC; Yaqoob, M, 1993) |
| "Diabetic nephropathy is invariably associated with proteinuria." | ( Haramoto, T; Hironaka, K; Kanwar, YS; Makino, H; Ota, Z; Shikata, K; Yamasaki, Y, 1993) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease in developed countries." | ( Lang, R; Lishner, M; Rachmani, R; Ravid, M, 1996) |
| "Diabetic nephropathy is characterized by renal hypertrophy, thickening of basement membranes, and accumulation of extracellular matrix in the glomerular mesangium and the interstitium." | ( Guo, J; Jin, Y; Sharma, K; Ziyadeh, FN, 1996) |
| "Diabetic nephropathy is associated with an increase in perinatal mortality and morbidity in uncontrolled pregnant patients." | ( Bar, J; Boner, G; Erman, A; Hod, M; Karp, M; Ovadia, J; Peled, Y; Rabinerson, D; van Dijk, DJ; Weintraub, N, 1995) |
| "Diabetic nephropathy is preceded by 'hyperfiltration' mediated by dilatation of the afferent arterioles to the glomeruli by means of IGF-1, prostaglandins, bradykinin, nitric oxide and atrial natriuretic peptide, together with constriction of the efferent arterioles by local thromboxane A2." | ( Wardle, EN, 1996) |
| "Diabetic nephropathy is a progressive renal disease with thickening of the glomerular basement membrane and mesangial expansion and proliferation as histological hallmarks." | ( Frölich, M; Geelhoed-Duijvestijn, PH; Lemkes, HH; van der Meer, FJ; van der Pijl, JW; van der Woude, FJ; van Es, LA, 1997) |
| "Diabetic nephropathy is a glomerular disease due to uncontrolled diabetes and genetic factors." | ( Alhenc-Gelas, F; Bauduceau, B; Bled, F; Chaillous, L; Chatellier, G; Dusselier, L; Gallois, Y; Halimi, S; Jeunemaitre, X; Kahal, Z; Marre, M; Muller, A; Passa, P; Rodier, M; Sackmann, H; Sert, C, 1997) |
| "Diabetic nephropathy is a common complication in patients with either type I or type II diabetes." | ( Alzahabi, B; Kapoor, S; Kurnik, BR; Kurnik, PB; McGowan, TA; Sharma, K; Weisberg, LS; Ziyadeh, FN, 1997) |
| "Diabetic nephropathy is the most common cause of end-stage renal disease (ESRD) in the United States, and accounts for 35% of all the patients with ESRD entering a dialysis program; 63% of patients with diabetic nephropathy have type II diabetes mellitus." | ( Ruilope, LM, 1997) |
| "Diabetic nephropathy is the major determinant of premature morbidity and mortality both in insulin-dependent (IDDM) and in non-insulin dependent-diabetes mellitus (NIDDM)." | ( Grzeszczak, W; Lacka, B; Zukowska-Szczechowska, E; Zychma, M, 1997) |
| "Clinical diabetic nephropathy is a well-recognized cause of increased morbidity and mortality in patients with type 1 diabetes." | ( Casani, A; Chiarelli, F; Morgese, G; Pinelli, L; Verrotti, A, 1998) |
| "Diabetic nephropathy is one of the major complications of insulin-dependent diabetes mellitus (IDDM), with proteinuria being the main clinical manifestation of diabetic nephropathy." | ( Barosi, M; Brunetti, M; Garattini, L; Salvioni, F, 1997) |
| "The prevalence of diabetic nephropathy is greater in nonwhite patients with type II diabetes, including the Chinese, and genetic variation appears to have a role." | ( Chan, JC; Li, PK; Poon, E; Wong, TY, 1999) |
| "Diabetic nephropathy is as likely to develop in long-duration non-insulin-dependent diabetes (type 2) as in insulin-dependent diabetes mellitus (type 1)." | ( Friedman, EA, 1999) |
| "Although diabetic nephropathy is often a low renin state, the renin system appears to be implicated in its pathogenesis." | ( De'Oliveira, JM; Fisher, ND; Gordon, M; Hollenberg, NK; Laffel, LM; Passan, DR; Porter, LE; Price, DA; Williams, GH, 1999) |
| "Diabetic nephropathy is the most common cause of end-stage renal disease in the United States." | ( Bain, RP; Berl, T; Lewis, EJ; Lewis, JB; Rohde, RD, 1999) |
| "Diabetic nephropathy is characterized by glomerular hypertrophy." | ( Al-Douahji, M; Alpers, CE; Brown, PA; Brugarolas, J; Shankland, SJ; Stehman-Breen, CO, 1999) |
| "In summary, diabetic nephropathy is characterized by a multifactorial disease process." | ( Torffvit, O, 1999) |
| "Diabetic nephropathy is a leading cause of end-stage renal disease and is characterized by excessive deposition of extracellular matrix (ECM) proteins in the glomeruli." | ( Han, DC; Kim, SI; Lee, HB, 2000) |
| "Diabetic nephropathy is the most common cause of end-stage renal disease in the developed world." | ( Anzalone, DA; Atkins, RC; Clarke, WR; Hunsicker, LG; Lewis, EJ; Ritz, E; Rodby, RA; Rohde, RD, 2000) |
| "Diabetic nephropathy is one of the main causes of renal end-stage disease." | ( Lehmann, R; Schleicher, ED, 2000) |
| "Diabetic nephropathy is characterized by an accumulation of mesangium matrix that correlates well with the loss of kidney function." | ( Death, AK; Fisher, E; Lyons, JG; Martell, SY; McLennan, SV; Williams, PF; Yue, DK, 2000) |
| "Diabetic nephropathy is a major cause of renal failure." | ( Hovind, P; Parving, HH; Rossing, P; Smidt, UM; Tarnow, L, 2001) |
| "Diabetic nephropathy is one of the leading causes of end-stage renal disease." | ( Gregersen, G; Kvetny, J; Pedersen, RS, 2001) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease in European countries and is associated with an enhanced renal synthesis of endothelin (ET)-1." | ( Bauer, C; Hocher, B; Jacobi, J; Lun, A; Neumayer, HH; Priem, F; Raschack, M; Reinbacher, D; Schwarz, A, 2001) |
| "Diabetic nephropathy is characterised by an increase in glomerular and tubular fibrosis that compromises kidney function." | ( Bak, M; Flyvbjerg, A; Hill, C; Logan, A; Rasch, R, 2001) |
| "Diabetic nephropathy is a major complication of diabetes leading to thickening of the glomerular basement membrane, glomerular hypertrophy, mesangial expansion, and overt renal disease." | ( Aaltonen, P; Ahola, H; Aström, E; Grönholm, T; Holthöfer, H; Jaakkola, I; Luimula, P; Palmen, T; Palojoki, E; Tikkanen, I, 2001) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease." | ( Brenner, BM; Cooper, ME; de Zeeuw, D; Keane, WF; Mitch, WE; Parving, HH; Remuzzi, G; Shahinfar, S; Snapinn, SM; Zhang, Z, 2001) |
| "Diabetic nephropathy is characterized functionally by glomerular hyperfiltration and albuminuria and histologically by the expansion of glomerular mesangium." | ( Haneda, M; Kikkawa, R; Koya, D, 2001) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease worldwide." | ( Chu, WS; Chung, SH; Ha, H; Kim, JK; Lee, HB, 2001) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease." | ( Brenner, BM; Cooper, ME; de Zeeuw, D; Keane, WF; Mitch, WE; Parving, HH; Remuzzi, G; Shahinfar, S; Snapinn, SM; Zhang, Z, 2001) |
| "Progression of diabetic nephropathy is closely associated with morphological changes in glomeruli, such as thickening of the glomerular basement membrane, mesangial expansion, and glomerulosclerosis." | ( Okada, M; Takemura, T; Yanagida, H; Yoshioka, K, 2002) |
| "Diabetic nephropathy is a glomerular disease, which causes most of premature mortality observed in diabetic patients." | ( Larger, E; Marre, M, 2001) |
| "Diabetic nephropathy is the most common cause of end-stage renal failure in patients starting dialysis in the developed world." | ( Boulton-Jones, JM; Deighan, CJ; Joss, N; Paterson, KR; Simpson, K, 2002) |
| "Diabetic nephropathy is becoming a major medical problem with increasing numbers of these patients progressing to end stage renal disease, thus requiring renal replacement therapy." | ( Abdel-Rahman, E; Bolton, WK, 2002) |
| "Diabetic glomerulosclerosis is the most frequent cause of renal disease in patients with type II diabetes mellitus (DM), sometimes accompanied by vascular lesions." | ( Castellano, I; Covarsí, A; Ferrando, L; Gómez-Martino, JR; Novillo, R, 2002) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease (ESRD) in Western and Asian countries." | ( Ribeiro, AB; Zanella, MT, 2002) |
| "Diabetic nephropathy is characterized by the rapid onset of hypertrophy and ECM expansion." | ( Abboud, HE; Barnes, JL; Garcia, S; Gooch, JL, 2003) |
| "Diabetic nephropathy is one of the primary diseases of refractory renal failure and heads the list of patients undergoing dialysis." | ( Hata, T; Owada, A; Suda, S, 2002) |
| "Diabetic nephropathy is a major cause of end stage renal failure." | ( Agarwal, DK, 2002) |
| "Diabetic nephropathy is the most frequent cause of end-stage renal failure." | ( Buraczyńska, M; Ksiazek, A; Ksiazek, P; Nowicka, T; Spasiewicz, D; Łopatyński, J, 2002) |
| "Diabetic nephropathy is a leading cause of end-stage renal disease in industrialized countries." | ( Amano, S; Inagaki, Y; Koga, K; Makita, Z; Okamoto, T; Saga, T; Takeuchi, M; Yamagishi, S; Yoshizuka, M, 2002) |
| "The pathogenesis of diabetic nephropathy is complex and characterized by altered expression of many genes, including growth factors, apoptotic regulators, cellular matrix components, and cytoskeletal proteins." | ( Brady, HR; Dolan, V; Hensey, C, 2003) |
| "Diabetic nephropathy is major long-term complication of diabetes mellitus a social and civilization-related disease." | ( Bartłomiejczyk, I; Kropiewnicka, E; Paczek, L; Senatorski, G, 2002) |
| "Diabetic nephropathy is the most common cause of end-stage renal failure in the Western world." | ( How, HY; Sibai, BM, 2002) |
| "Diabetic nephropathy is a leading cause of end-stage renal disease in industrialized countries." | ( Amano, S; Inagaki, Y; Koga, K; Okamoto, T; Takeuchi, M; Yamagishi, S, 2002) |
| "Diabetic nephropathy is associated with enhanced renal synthesis of endothelin (ET)-1." | ( Clozel, M; Ding, SS; Hess, P; Qiu, C; Xi, JF; Zheng, N, 2003) |
| "The first sign of diabetic nephropathy is microalbuminuria, but its predictive role of progression to overt nephropathy in type 2 diabetes has not yet been clarified." | ( Bargero, G; Biggeri, A; Bruno, G; Cavallo Perin, P; Ferrero, S; Merletti, F; Pagano, G, 2003) |
| "Risk factors for diabetic nephropathy are discussed, and include hyperglycemia, hypertension, angiotensin II, proteinuria, dyslipidemia, smoking, and anemia." | ( Mohanram, A; Toto, RD, 2003) |
| "Diabetic nephropathy is characterized by excessive deposition of extracellular matrix (ECM) in the kidney." | ( Ha, H; Jiang, Z; Lee, HB; Yang, Y; Yu, MR, 2003) |
| "Diabetic nephropathy is one of the most common microvascular complications of diabetes mellitus and the leading cause of end-stage renal disease in developed countries." | ( Anderson, PW; Tuttle, KR, 2003) |
| "Diabetic nephropathy is a leading cause of end-stage renal failure." | ( Kido, Y; Makino, H; Matsuda, M; Nagase, R; Ogawa, D; Okada, S; Shikata, K; Shikata, Y; Usui, H; Wada, J, 2003) |
| "Diabetic nephropathy is now the leading cause of end-stage renal diseases, and glomerular sclerotic injury is an initial event that provokes renal dysfunction during processes of diabetes-linked kidney disease." | ( Mizuno, S; Nakamura, T, 2004) |
| "Diabetic nephropathy is characterized by increased urinary albumin excretion and loss of renal function." | ( Campbell, RC; Remuzzi, G; Ruggenenti, P, 2003) |
| "In conclusions, diabetic nephropathy is a main determinant of plasma tHcy elevation in type 2 diabetic patients." | ( Aso, Y; Okumura, K, 2003) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease." | ( Forsblom, C; Groop, PH; Havana, M; Holthöfer, H; Pätäri, A; Taipale, H, 2003) |
| "Diabetic nephropathy is characterized by early hypertrophy in both glomerular and tubuloepithelial elements." | ( Chuang, LY; Guh, JY; Huang, YL; Hung, MY; Liao, TN; Liu, SF; Yang, YL, 2004) |
| "Patients with diabetic nephropathy are at elevated cardiovascular risk." | ( Bostom, AG; Friedman, AN; Hunsicker, LG; Selhub, J, 2004) |
| "Diabetic nephropathy is characterized by an expansion of glomerular mesangium, caused by mesangial cell proliferation and excessive accumulation of extracellular matrix (ECM) proteins, which eventually leads to glomerulosclerosis and renal failure." | ( Ahn, JD; Chang, YC; Kaneda, Y; Kim, HJ; Kim, YD; Kim, YH; Kwon, HS; Lee, HJ; Lee, IK; Lee, KU; Morishita, R; Park, JY; Park, KG; Park, KK; Yoon, KH, 2004) |
| "Diabetic nephropathy is the leading cause of end stage renal disease (ESRD), and given that treating this condition is a considerable economic burden, the prevention of ESRD is a major public health goal." | ( Rayner, B, 2004) |
| "Diabetic nephropathy is the single most common cause of chronic renal failure requiring dialysis." | ( Boulton-Jones, JM; Brown, C; Deighan, CJ; Ferguson, C; Joss, N; Paterson, KR, 2004) |
| "Diabetic nephropathy is the main cause of end-stage renal disease requiring dialysis in developed countries." | ( Alperovich, G; Aran, JM; Cruzado, JM; Fillat, C; Grinyó, JM; Herrero-Fresneda, I; Lloberas, N; Riera, M; Torras, J; Vidal, A, 2004) |
| "1." | ( Anjaneyulu, M; Chopra, K, 2004) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease in the Western hemisphere." | ( Prabhakar, SS, 2004) |
| "Diabetic nephropathy is a relatively common microvascular complication in people suffering from diabetic mellitus." | ( Kalia, K; Mistry, K; Sharma, S, 2004) |
| "Diabetic nephropathy is associated with increased albuminuria and accumulation of extracellular matrix proteins within the kidney." | ( Allen, TJ; Cao, Z; Cooper, ME; Ma, G, 2004) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease (ESRD)." | ( Brenner, BM; Keane, WF; Mohanram, A; Shahinfar, S; Toto, RD; Zhang, Z, 2004) |
| "Diabetic nephropathy is associated with elevated markers for both coagulation and inflammation." | ( Aso, Y; Inukai, T; Matsutomo, R; Okumura, K; Takebayashi, K; Wakabayashi, S; Yoshida, N, 2004) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease (ESRD)." | ( Bakris, GL; McCullough, PA; Toto, RD, 2005) |
| "Diabetic nephropathy is characterized by progressive loss of renal function, persistent proteinuria, and relentless accumulation of extracellular matrix leading to glomerulosclerosis and interstitial fibrosis." | ( Bastacky, S; Dai, C; Li, Y; Liu, Y; Xia, J; Yang, J, 2004) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease, for which effective therapy to prevent the progression at advanced stages remains to be established." | ( Ebihara, K; Hidaka, S; Kawachi, H; Koshikawa, M; Mori, K; Mukoyama, M; Nakao, K; Ogawa, Y; Sawai, K; Suganami, T; Sugawara, A; Tanaka, T; Vinson, C; Yokoi, H, 2005) |
| "Diabetic nephropathy is continuing to rise in incidence, despite awareness of tight glycemic control and blood pressure." | ( McGowan, TA; Sharma, K; Zhu, Y, 2004) |
| "Diabetic nephropathy is characterised by an increased risk of cardiovascular morbidity and mortality." | ( Borch-Johnsen, K; Hansen, BV; Hildebrandt, P; Parving, HH; Tarnow, L, 2005) |
| "Diabetic nephropathy is characterized by glomerular and tubular hypertrophy, and angiotensin II receptor blockers (ARBs) are known to prevent renal hypertrophy in diabetic patients." | ( Adler, SG; Cheon Park, H; Ha, SK; Han, DS; Kang, SW; Natarajan, R; Ryu, DR; Xu, ZG; Yoo, TH, 2005) |
| "Diabetic nephropathy is a common complication in patients with type 2 diabetes that may increase atherothrombotic risk." | ( Fowler, B; Herrmann, W; Kuhlmann, MK; Makowski, J; Obeid, R; Schorr, H, 2005) |
| "Diabetic nephropathy is a serious complication of diabetes associated with a poor prognosis which deteriorates to end-stage renal disease." | ( Godes, M; Hocher, B; Neumayer, HH; Richter, CM; Simon, K; Thöne-Reinke, C; Thormählen, D, 2004) |
| "Diabetic nephropathy is characterised by hypertension and persistent proteinuria." | ( Barnett, AH, 2005) |
| "Diabetic nephropathy is one of the most common diseases leading to fibrosis and end-stage renal disease (ESRD) world wide." | ( Chai, Q; Krag, S; Ledet, T; Wogensen, L, 2005) |
| "The risk of diabetic nephropathy is partially genetically determined." | ( Baelde, H; Bakker, SJ; Bartram, CR; Brinkkoetter, P; Cerna, M; de Heer, E; Fischer, C; Hammes, HP; Hohenadel, D; Janssen, B; Köppel, H; Mathieson, P; Meyer, J; Nawroth, P; Peters, V; Rind, N; Romzova, M; Rondeau, E; Rychlik, I; Saleem, MA; Sauerhoefer, S; van der Woude, FJ; Yard, BA; Zirie, M; Zschocke, J, 2005) |
| "Diabetic nephropathy is now the number one cause of end stage renal failure in Malaysia." | ( Wong, JS, 2005) |
| "Diabetic nephropathy is characterized by excessive accumulation of extracellular matrix (ECM) in the kidney." | ( Ha, H; Lee, HB, 2005) |
| "Diabetic nephropathy is one of the major microvascular complications in diabetes and is the leading cause of end-stage renal disease worldwide." | ( Eguchi, K; Hirokoshi, K; Ichinose, K; Kitayama, H; Maeshima, Y; Makino, H; Sugiyama, H; Takazawa, Y; Yamamoto, Y; Yamasaki, Y, 2005) |
| "Clinical diabetic nephropathy is characterized by an earlier functional phase in which hyperglycaemia is accompanied by an increased glomerular filtration rate and microalbuminuria; the persistence of this high-flow and high-pressure state, added to a poor control of hyperglycaemia, fosters renal damage and proteinuria, accompanied by a decline in glomerular filtration rate and progression to end-stage renal disease." | ( Leon, CA; Raij, L, 2005) |
| "Diabetic nephropathy is currently the most common cause of end-stage renal disease." | ( Hume, WE; Kitoh, M; Nagamine, J; Nagata, R; Nakagawa, T; Ono-Kishino, M; Sugaru, E; Taiji, M; Tokunaga, T, 2006) |
| "Diabetic nephropathy is a serious microvascular complication and one of the main causes of end-stage renal disease." | ( Anjaneyulu, M; Chopra, K; Kulkarni, SK; Sharma, S, 2006) |
| "Diabetic nephropathy is the most frequent cause of terminal renal failure, requiring renal replacement therapy." | ( Prabhakar, SS, 2005) |
| "Early diabetic nephropathy is characterized by renal hypertrophy that is mainly due to proximal tubular hypertrophy." | ( Isono, M; Isshiki, K; Kashiwagi, A; Koya, D; Sakaguchi, M; Sugimoto, T, 2006) |
| "Diabetic nephropathy is a life-threatening disease associated with diabetes mellitus." | ( Kadomatsu, K; Kawai, H; Kosugi, T; Matsuo, S; Muramatsu, T; Sato, W; Takei, Y; Yuzawa, Y, 2006) |
| "Diabetic nephropathy is now the most common cause of end-stage renal disease." | ( Hume, WE; Kitoh, M; Nagamine, J; Nagata, R; Nakagawa, T; Ono-Kishino, M; Sugaru, E; Taiji, M; Tokunaga, T, 2006) |
| "Diabetic nephropathy is a severe complication and few studies have described the early morphological changes over time." | ( Berg, UB; Jaremko, GA; Perrin, NE; Torbjörnsdotter, TB, 2006) |
| "Diabetic nephropathy is the leading cause of chronic renal failure in countries in the western world." | ( Doggrell, SA, 2006) |
| "Diabetic nephropathy is one of the major complications of diabetes." | ( Abassi, Z; Mirsky, N; Morgan, M; Nakhoul, F; Sussan, S, 2006) |
| "Diabetic nephropathy is a life-threatening complication of diabetes mellitus." | ( Gu, Y; Hiura, A; Inoue, K; Matsuno, S; Qi, M; Sakata, N; Sumi, S; Sunamura, M; Yamamoto, C, 2006) |
| "Diabetic nephropathy is a major complication of diabetes and a leading cause of end-stage renal diseases in the U." | ( Cao, W; Knapp, RR; Lau, K; Ma, JX; Mott, R; Wang, JJ; Zhang, SX, 2006) |
| "Diabetic nephropathy is characterized by an expansion of the glomerular mesangium, caused by mesangial cell proliferation and an excessive accumulation of extracellar matrix (ECM) proteins, which eventually leading to glomerulosclerosis." | ( Chae, YM; Kang, YN; Kim, HC; Lee, SS; Noh, HJ; Park, KK, 2006) |
| "Diabetic nephropathy is a microvascular complication of diabetes." | ( Barit, D; Cooper, ME; Giunti, S, 2006) |
| "Thus, diabetic nephropathy is currently the number one cause of end-stage renal disease in the Western world." | ( Bakris, GL; Sarafidis, PA, 2006) |
| "Diabetic nephropathy is the major cause of end-stage renal disease." | ( Chou, P; Lin, CH; Tsai, ST; Tung, TH; Yang, WC, 2007) |
| "Albuminuria in diabetic nephropathy is due to endothelial dysfunction, a loss of negative charges in the basement membrane, and changes a of the slit-membrane diaphragm composition." | ( Boehne, M; Haller, H; Holthofer, H; Kirsch, T; Leitges, M; Lindschau, C; Meier, M; Menne, J; Ociepka, R; Park, JK; Rinta-Valkama, J, 2006) |
| "Diabetic nephropathy is a major cause of morbidity and mortality." | ( Palm, F, 2006) |
| "Diabetic nephropathy is the leading cause of ESRD." | ( Jha, V; Modi, GK, 2006) |
| "Diabetic kidney disease is associated with lower haemoglobin in comparison with non-diabetic kidney disease, especially at GFR <60 ml/min." | ( Mathieson, PW; Ravanan, R; Smith, RM; Spiro, JR, 2007) |
| "Advanced diabetic nephropathy is characterized by abnormal synthesis of extracellular matrix (ECM) proteins, such as collagen I (COL I)." | ( Asano, M; Fukui, M; Hasegawa, G; Hosoda, H; Kamiuchi, K; Nakajima, T; Nakamura, N; Tominaga, M; Yamasaki, M; Yoshikawa, T, 2006) |
| "Diabetic nephropathy is the main cause of end-stage renal disease." | ( Hume, WE; Kitoh, M; Nagamine, J; Nagata, R; Nakagawa, T; Ono-Kishino, M; Sugaru, E; Taiji, M; Tokunaga, T, 2007) |
| "Diabetic nodular glomerulosclerosis is considered to be the specific renal lesion of diabetes mellitus (DM)." | ( Abe, T; Chihara, J; Harada, A; Hirakata, H; Iida, M; Katafuchi, R; Kumagai, H; Nakamoto, M; Okuda, S; Onoyama, K; Oochi, N; Sanai, T; Yoshimitsu, T, 2007) |
| "Diabetic nephropathy is a serious complication of both type 1 and type 2 diabetes, and, unless arrested, leads to end-stage renal disease." | ( Dakshinamurthy, KV; Girisesh, G; Lu, X; Nagalla, SR; Neelima, G; Pattee, P; Rao, PV; Roberts, CT; Standley, M, 2007) |
| "Diabetic nephropathy is a major complication of diabetes leading to end-stage renal disease, which requires hemodialysis." | ( Kaneko, S; Koike, N; Takamura, T, 2007) |
| "Although diabetic nephropathy is the most common type of chronic kidney disease found in pregnant women, a variety of other primary and systemic kidney diseases also commonly occur." | ( Fischer, MJ, 2007) |
| "Diabetic nephropathy is the leading cause of chronic renal failure (CRF) in Europe." | ( Berwert, L; Teta, D; Zanchi, A, 2007) |
| "Diabetic nephropathy is currently the most common cause of end-stage renal disease (ESRD) in the western world." | ( Grahovac, G; Kalluri, R; Sugimoto, H; Zeisberg, M, 2007) |
| "Diabetic nephropathy is the most serious of complications in diabetes mellitus." | ( Cho, BP; Chung, CH; Koh, JH; Lee, BJ; Lee, EY; Lee, MY; Shin, JY; Shin, YG; Won, CS, 2007) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease (ESRD) in Japan and other Westernized countries." | ( Arai, H; Nishida, Y; Shuto, E; Takeda, E; Taketani, Y; Tanaka, R; Uebanso, T; Yamamoto, H; Yamanaka-Okumura, H, 2007) |
| "Diabetic nephropathy is the most common cause of end-stage renal failure in the United States." | ( Liu, S; Shi, L; Wang, S, 2007) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease." | ( Guan, Y; Zheng, F, 2007) |
| "Early stages of diabetic nephropathy are associated with renal hemodynamic changes that are, at least in part, attributable to the dysbalance of vasoactive factors that control afferent and efferent arteriolar tone resulting in increased glomerular capillary pressure." | ( Anderson, S; Komers, R; Lindsley, JN; Oyama, TT; Schutzer, W; Xue, H, 2007) |
| "Diabetic nephropathy is associated with hypoalbuminaemia and hyperfibrinogenaemia." | ( Castellino, P; Ciarambino, T; Cioffi, M; De Feo, P; Gesuè, L; Giordano, M; Gresele, P; Lucidi, P; Paolisso, G, 2008) |
| "Diabetic nephropathy is an important cause of morbidity and mortality in patients with either type 1 or type 2 diabetes mellitus." | ( Niecestro, R; Raz, I; Weiss, R, 2007) |
| "Diabetic nephropathy is characterized by excessive amassing of extracellular matrix (ECM) with thickening of glomerular and tubular basement membranes and increased amount of mesangial matrix, which ultimately progress to glomerulosclerosis and tubulo-interstitial fibrosis." | ( Chen, S; Chugh, S; Danesh, FR; Kanwar, YS; Sun, L; Wada, J; Wallner, EI; Xie, P, 2008) |
| "Diabetic nephropathy is characterised by increased glomerular permeability to proteins, thickening of the glomerular basement membrane, and excessive extracellular matrix accumulation in the mesangium." | ( Camussi, G; Gruden, G; Perin, PC, 2005) |
| "Diabetic nephropathy is presently the first reason of end stage renal failure in Europe and the USA and its worldwide prevalence is rapidly increasing." | ( Gabellini, D; Maestroni, A; Ruggieri, D; Zerbini, G, 2006) |
| "Diabetic kidney disease is associated with monocyte chemoattractant CC chemokine ligand 2 (CCL2)-dependent glomerular and interstitial macrophage recruitment." | ( Anders, HJ; Buchner, K; Clauss, S; Eulberg, D; Klussmann, S; Kulkarni, O; Ninichuk, V; Radomska, E; Schmid, H; Segerer, S; Selve, N, 2008) |
| "Diabetic nephropathy is traditionally considered to be a primarily glomerular disease, although this contention has recently been challenged." | ( Farrington, K; Singh, DK; Winocour, P, 2008) |
| "Diabetic nephropathy is a major cause of lower-limb amputation." | ( Fujimoto, K; Hisatomi, A; Inubushi, T; Ito, I; Kashiwagi, A; Maegawa, H; Morikawa, S; Nishio, Y; Sakaguchi, M; Suzuki, E; Takeda, J; Uzu, T; Yoshimura, T, 2008) |
| "Diabetic nephropathy is the leading cause of death that affects more than 40% of diabetic patients." | ( Mahboob, T; Shahid, SM, 2008) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease in developed countries." | ( Hollenberg, NK; Lewis, EJ; Lewis, JB; Parving, HH; Persson, F, 2008) |
| "Diabetic nephropathy is one of the leading causes of end-stage renal disease (ESRD)." | ( Al-Homrany, MA; El Sherif, AK; Irshaid, YM; Omar, HA, 2009) |
| "Diabetic nephropathy is one of the main causes of end-stage renal disease (ESRD) and is associated with elevated cardiovascular morbidity and mortality." | ( Cattaneo, D; Cortinovis, M; Perico, N; Remuzzi, G, 2008) |
| "Diabetic nephropathy is an important risk factor for cardiovascular diseases (CVD)." | ( Cornell, E; Knowler, WC; Krakoff, J; Le, DS; Miles, R; Savage, PJ; Tracy, RP, 2008) |
| "Diabetic nephropathy is the leading cause of end-stage kidney disease in developed countries and is related to chronic hyperglycaemia." | ( Candido, R; Cocchietto, M; Fabris, B; Sava, G; Stebel, M; Toffoli, B; Zorzin, L, 2008) |
| "Diabetic nephropathy is the most common cause of end-stage renal disease in developed countries, and its prevalence is increasing." | ( Brown, WV, 2008) |
| "Diabetic nephropathy is the most serious complication in diabetes mellitus." | ( Chung, CH; Koh, JH; Koh, SB; Lee, EY; Lee, MY; Nam, SM; Park, JH; Shin, JY; Shin, YG, 2009) |
| "Diabetic nephropathy is a serious complication for patients with diabetes mellitus." | ( Chopra, K; Kuhad, A, 2009) |
| "Diabetic nephropathy is characterized by decreased expression of bone morphogenetic protein-7 (BMP-7) and decreased podocyte number and differentiation." | ( Goldschmeding, R; Gray, J; Leeuwis, JW; Lyons, KM; Nguyen, TQ; Torti, SV; Turk, T, 2009) |
| "Diabetic nephropathy is a debilitating disease that leads to end-stage renal failure in the Western world." | ( Chakrabarti, S; Chiu, J; Farhangkhoee, H; Khan, ZA, 2009) |
| "Diabetic kidney disease is characterized by persistent albuminuria (>300 mg/dl or >200 microg/min) that is confirmed on at least 2 occasions 3 to 6 months apart, with a progressive decline in the glomerular filtration rate (GFR), elevated arterial blood pressure, and an increased risk for cardiovascular morbidity and mortality." | ( Bichu, P; Khan, A; Nistala, R; Sowers, JR; Whaley-Connell, A, 2009) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease in the United States." | ( MacMillan-Crow, LA; Munusamy, S, 2009) |
| "Diabetic nephropathy is a common cause for end-stage renal disease." | ( Manna, P; Sil, PC; Sinha, M, 2009) |
| "Diabetic nephropathy is characterized by increased oxidative stress and mitochondrial dysfunction." | ( Lash, LH; Terlecky, SR; Zhong, Q, 2009) |
| "An early feature of diabetic nephropathy is the alteration of the glomerular basement membrane (GBM), which may result in microalbuminuria, subsequent macroproteinuria, and eventual chronic renal failure." | ( Ahn, EM; Ahn, HY; Ha, TS; Hong, EJ, 2009) |
| "Diabetic nephropathy is one of the most common causes of end-stage renal failure." | ( Basu, R; Chow, FL; Herzenberg, AM; Janzek, E; Kassiri, Z; Liu, GC; Loibner, H; Oudit, GY; Penninger, JM; Scholey, JW; Schuster, M; Zhong, J; Zhou, J, 2010) |
| "Diabetic nephropathy is one of the most severe diabetic microangiopathies and accounting for approximately one-third of all cases of end-stage renal disease." | ( Cui, X; Li, W; Li, X; Sun, X; Zhu, Q, 2010) |
| "Diabetic nephropathy is one of the major causes of renal failure, which is accompanied by the production of reactive oxygen species (ROS)." | ( Fang, D; Huang, Z; Jiang, T; Lin, Y; Zhang, DD; Zhang, Z, 2010) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease, and both the incidence and prevalence of diabetic nephropathy continue to increase." | ( Bolton, WK; Turgut, F, 2010) |
| "Diabetic nephropathy is the most prevalent cause of end-stage renal disease." | ( Kheiri, S; Momeni, A; Seirafian, S; Shahidi, S; Taheri, S, 2010) |
| "Diabetic nephropathy is associated with lipid deposits in the kidney." | ( Kido, Y; Kobayashi, Y; Kuwahata, M; Murata, T; Nakabou, Y; Suzuki, I; Tada, E; Tanigawa, K; Yokoyama, M, 2010) |
| "Diabetic nephropathy is the most common and most rapidly growing cause of end-stage renal failure in developed countries." | ( Declèves, AE; Sharma, K, 2010) |
| "Diabetic nephropathy is a complication of diabetes mellitus." | ( Chowdary, NV; Desai, V; Prabodh, S; Prakash, DS; Shekhar, R; Sudhakar, G, 2011) |
| "Diabetic nephropathy is a leading cause of end-stage renal disease." | ( Allen, TJ; Calkin, AC; Cooper, ME; Forbes, JM; Giunti, S; Jandeleit-Dahm, KA; Thomas, MC, 2010) |
| "Diabetic nephropathy is the leading cause of kidney failure in the developed world." | ( Cox, AJ; Kelly, DJ; Qi, W; Tan, SM; Zhang, Y, 2011) |
| "Diabetic nephropathy is characterized as the progressive development of renal insufficiency in a setting of hyperglycemia." | ( Chen, CC; Chen, HC; Lee, HJ; Lee, WC; Lin, PY; Ou, TT; Wang, CY; Wang, J; Wen, MC, 2010) |
| "Development of diabetic nephropathy is accompanied by changes in integrin-mediated cell-matrix interactions." | ( Cordasic, N; Hartner, A; Hilgers, KF; Kupraszewicz-Hutzler, M; Menendez-Castro, C; Rascher, W; Volkert, G; Yabu, JM, 2010) |
| "Diabetic nephropathy is characterized by abnormal angiogenesis, and this is driven by several factors, including hyperglycaemia and ischaemia." | ( Chang, YS; Choi, BS; Chung, HW; Chung, S; Kim, HW; Kim, MY; Kim, YS; Lim, JH; Park, CW; Shin, SJ, 2011) |
| "Diabetic kidney disease is the leading cause of end-stage renal disease worldwide." | ( Campbell, KN; Mundel, P; Raij, L, 2011) |
| "Diabetic nephropathy is the common cause of leading to end stage of renal disease (ESRD)." | ( Ahmadvand, H; Delfan, B; Khalatbari, AR; Tamjidipoor, A; Tavafi, M, 2011) |
| "The pathogenesis of diabetic nephropathy is complex and still not fully elucidated." | ( Hovind, P; Johnson, RJ; Parving, HH; Rossing, P, 2011) |
| "Diabetic nephropathy is a major cause of renal failure in diabetes mellitus (DM)." | ( Chen, JF; Li, HW; Song, HF; Sun, NL, 2011) |
| "Diabetic nephropathy is the most frequent cause of end stage renal disease (ESRD)." | ( Cammarota, S; Citarella, A; de Portu, S; Mantovani, LG; Menditto, E, 2011) |
| "Diabetic nephropathy is the most common cause of end-stage renal disease in the western world." | ( Schjoedt, KJ, 2011) |
| "Diabetic nephropathy is associated with dedifferentiation of podocytes, losing the specialized features required for efficient glomerular function and acquiring a number of profibrotic, proinflammatory, and proliferative features." | ( Cooper, ME; Herman-Edelstein, M; Kantharidis, P; Saleem, M; Thallas-Bonke, V; Thomas, MC, 2011) |
| "Diabetic nephropathy is one of the main causes of end-stage renal disease, in which the development of tubular damage depends on factors such as high glucose levels, albuminuria and advanced glycation end-product." | ( Abaterusso, C; Gambaro, G; Lupo, A; Masola, V; Onisto, M; Tibaldi, E, 2011) |
| "Diabetic nephropathy is the most serious complication in diabetes mellitus." | ( Cho, EJ; Choi, R; Chung, CH; Hyun, MR; Kim, BH; Lee, ES; Lee, EY; Lee, MY; Naowaboot, J; Yang, YC, 2011) |
| "Diabetic nephropathy is characterized by accumulation of glomerular extracellular matrix proteins, such as fibronectin (FN)." | ( Huang, H; Huang, K; Lan, T; Liu, P; Liu, W; Peng, J; Shen, X; Wang, L; Xia, P; Xie, X; Xu, S, 2011) |
| "Early diabetic nephropathy is characterized by glomerular hyperpermeability as a result of impaired glomerular filtration structure caused by hyperglycemia, glycated proteins or irreversible advanced glycosylation endproducts (AGE)." | ( Choi, JY; Ha, TS; Lee, JS; Park, HY, 2011) |
| "Diabetic glomerulosclerosis is the hardening of the renal glomeruli that can lead to kidney failure." | ( Kang, MK; Kang, SW; Kang, YH; Kim, JK; Kim, JL; Li, J; Lim, SS, 2012) |
| "Diabetic nephropathy is a major cause of morbidity and mortality in diabetic patients." | ( Abd el-Latif, FF; Khalifa, M; Sayed, AA, 2012) |
| "Diabetic nephropathy is associated with glomerular hypertrophy, glomerulosclerosis, tubulointerstitial fibrosis, mesangial cell expansion, followed by albuminuria and reduction in glomerular filtration rate." | ( Balakumar, P; Kadian, S; Mahadevan, N, 2012) |
| "Diabetic nephropathy is the major cause of end-stage renal disease worldwide." | ( Kakoki, M; Sanford, RB; Smithies, O; Tomita, H, 2012) |
| "Diabetic nephropathy is the most common cause of chronic renal failure in industrialized countries." | ( Das, AM; Engeli, S; Haller, H; Schiffer, M; Stieger, N; Teng, B; Worthmann, K, 2012) |
| "Diabetic nephropathy is a common cause of end stage renal disease." | ( Alvarez Gregori, J; Cubero, JJ; Ferreira, F; Macias, J; Martinez-Gallardo, R; Robles, NR; Sanchez-Casado, E, 2012) |
| "Diabetic nephropathy is a serious complication of longstanding diabetes and its pathogenesis remains unclear." | ( Dang, H; Kamat, A; Yeh, CK; Zhang, BX; Zhang, HM, 2012) |
| "Diabetic nephropathy is a serious complication in patients with type 2 diabetes." | ( Araki, A; Araki, S; Iimuro, S; Ito, H; Kashiwagi, A; Maegawa, H; Nishio, Y; Ohashi, Y; Sakurai, T; Umegaki, H; Uzu, T, 2012) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease." | ( Bai, S; Fan, J; Fang, Y; Hou, W; Li, D; Tian, X; Tong, H, 2012) |
| "Especially diabetic nephropathy is a leading cause of morbidity and mortality, and its prevalence is increasing." | ( Kouroumichakis, I; Liakopoulos, V; Maltezos, E; Mikhailidis, DP; Papanas, N; Zarogoulidis, P, 2012) |
| "Diabetic nephropathy is characterized by glomerular mesangial expansion which could result from increased mesangial cell extracellular matrix synthesis induced by hyperglycemia." | ( Shibasaki, M; Tahara, A; Tomura, Y; Tsukada, J; Yatsu, T, 2012) |
| "Diabetic nephropathy is a complication of diabetes mellitus leading to end-stage renal disease." | ( Boreddy, PR; Chennasamudram, SP; Kudugunti, S; Moridani, MY; Vasylyeva, TL, 2012) |
| "Diabetic nephropathy is one of the most common microvascular complications of diabetes and the leading cause of end-stage renal disease." | ( Kang, DG; Kim, JS; Lee, AS; Lee, HS; Lee, SM; Lee, YJ; Yoon, JJ, 2012) |
| "Diabetic nephropathy is one of the important microvascular complications of diabetes; however, the main problem remains is the control of progression of nephropathy in diabetes." | ( Gupta, VB; Silawat, N, 2013) |
| "Diabetic nephropathy is a major complication of diabetes and tubulointerstitial fibrosis is one of its manifestations." | ( Ariga, T; Hosono, T; Iwakawa, K; Sasai, Y; Seki, T; Shen, Y; Yanagida, K, 2012) |
| "Diabetic nephropathy is the most common cause of end-stage renal disease and is a major risk factor for cardiovascular disease." | ( Grutzmacher, C; Morrison, ME; Park, S; Sheibani, N; Sorenson, CM; Zhao, Y, 2013) |
| "Diabetic nephropathy is a leading cause of end-stage renal failure all over the world." | ( Furuichi, K; Iwata, Y; Kaneko, S; Sakai, Y; Shimizu, M; Wada, T; Yokoyama, H, 2013) |
| "Diabetic nephropathy is a serious diabetic complication that leads to end stage renal disease." | ( Abd El-All, HS; Ewais, MM; Masoad, RE; Tawfik, MK, 2012) |
| "Diabetic nephropathy is a major complication of diabetes and a frequent cause of end-stage renal disease and recent studies suggest that podocyte damage may play a role in the pathogenesis of this." | ( Li, Z; Liu, S; Xu, J; Xu, P; Yang, Z, 2013) |
| "Although diabetic nephropathy is minimally observed on the C57BL/6 background, diabetic Tg26 mice exhibited a significant increase in glomerular injury compared with nondiabetic Tg26 mice and diabetic wild-type mice." | ( Chen, EY; Chuang, PY; D'Agati, V; He, JC; Kaufman, L; Klotman, PE; Liu, R; Ma'ayan, A; Mallipattu, SK; Zhong, Y, 2013) |
| "Diabetic nephropathy is the main cause of end-stage renal disease." | ( Bombardi, C; Castoldi, G; Corradi, B; di Gioia, CR; Leopizzi, M; Maestroni, S; Preziuso, C; Stella, A; Zerbini, G, 2013) |
| "Diabetic nephropathy is the major cause of end-stage renal disease worldwide." | ( Jose, MA; Kumar, BN; Sathyamurthy, D; Sheela, N, 2013) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease." | ( Alge, JL; Arthur, JM; Bhensdadia, NM; Hunt, KJ; Janech, MG; Lopes-Virella, MF; Mataria, MR; Michael Tucker, J; Neely, BA, 2013) |
| "Diabetic nephropathy is becoming increasingly common with the aging of our population and the obesity epidemic." | ( Appel, G, 2013) |
| "Diabetic nephropathy is characterized by a plethora of signaling abnormalities." | ( Arumugam, S; Lakshmanan, AP; Soetikno, V; Sone, H; Suzuki, K; Veeraveedu, PT; Watanabe, K, 2013) |
| "Diabetic nephropathy is a devastating disease that affects a growing number of diabetic patients." | ( Han, L; He, Y; Hu, P; Huang, M; Jiang, Z; Li, P; Liang, Q; Luo, G; Pang, L; Wang, Y; Xia, J, 2013) |
| "Worldwide, diabetic nephropathy is one of the leading causes of end-stage renal failure." | ( Agrawal, A; Dubey, GP; Ghosh, B; Rajak, M; Singh, RG, 2013) |
| "Diabetic glomerulosclerosis is characterized by accumulation of extracellular matrix proteins, mesangial expansion, and tubulointerstitial fibrosis." | ( Abdul, A; Deb, DK; Heilig, CW; James, LR; Nahman, NS; Riaz, H; Salameh, J, 2013) |
| "The evolution of diabetic nephropathy is incompletely accounted by current clinical tools." | ( Bouchard, J; Brachemi, S; Goupil, R; Madore, F; Pichette, V; Troyanov, S; Verhave, JC, 2013) |
| "The notion that diabetic nephropathy is the leading cause of renal fibrosis prompted us to investigate the effects of blood glucose fluctuation (BGF) under high glucose condition on kidney in the mice." | ( Cheng, X; Dang, Y; Gao, W; Li, Y; Liu, X; Peng, X; Ye, X, 2013) |
| "Diabetic nephropathy is one of the major causes of chronic kidney disease (CKD), consequently progression to end stage renal disease." | ( Duangchana, S; Silaratana, S; Sumransurp, S; Tasanarong, A, 2012) |
| "Diabetic nephropathy is a major risk of end-stage kidney disease." | ( Fujii, H; Fukagawa, M; Goto, S; Hirata, M; Kitazawa, R; Kitazawa, S; Kono, K; Nakai, K; Nishi, S; Shinohara, M, 2014) |
| "Diabetic nephropathy is one of the secondary complications of diabetes mellitus that is marked by changes in extracellular matrix components leading to end-stage renal failure." | ( Chilkunda, ND; Gurukar, MS; Mahadevamma, S, 2013) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease (ESRD)." | ( Kim, DK; Kim, SG; Lee, YK; Lim, CS; Na, KY, 2013) |
| "Diabetic nephropathy is the leading cause of chronic kidney disease and end-stage renal disease." | ( Dadras, F; Khoshjou, F, 2013) |
| "Diabetic nephropathy is characterized by elevated macrophage infiltration and inflammation." | ( Jadhav, A; Ndisang, JF, 2014) |
| "Diabetic nephropathy is the most common cause of chronic kidney failure and end-stage renal disease in the Western World." | ( Alvarez, ML; Eddy, E; Khosroheidari, M; Kiefer, J, 2013) |
| "Diabetic nephropathy is the primary cause of end-stage renal disease." | ( Chen, H; Huang, K; Jiao, L; Li, J; Peng, A; Petersen, RB; Zheng, L, 2014) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease worldwide, and is associated with a high risk of cardiovascular morbidity and mortality." | ( Diamant, M; Morsink, LM; Muskiet, MH; Smits, MM, 2014) |
| "Diabetic nephropathy is associated with premature senescence." | ( Cai, GY; Chen, XM; Cui, SY; Fu, B; Guo, YN; Hong, Q; Hu, X; Lv, Y; Wang, JC; Yin, Z, 2014) |
| "Diabetic nephropathy is one of the major causes of end stage renal disease, developing in approximately 30% of diabetic patients." | ( Fekete, A; Vannay, Á, 2014) |
| "Diabetic nephropathy is the leading cause of chronic renal disease and one of the major causes of cardiovascular mortality." | ( Agostinis, C; Cocchietto, M; Gallo, D; Harei, E; Masat, E; Sava, G; Veronesi, P, 2014) |
| "Diabetic nephropathy is the most frequent cause of terminal renal failure." | ( Dézsi, CA, 2014) |
| "Diabetic nephropathy is the leading cause of end-stage renal failure and accounts for 30-40 % of patients entering renal transplant programmes." | ( Banki, E; Csanaky, K; Degrell, P; Jancso, G; Juhasz, T; Kiss, P; Kovacs, K; Nagy, D; Reglodi, D; Tamas, A; Toth, G, 2014) |
| "The prevalence of diabetic nephropathy is increasing as a consequence of the global epidemic of diabetes, and the complications of diabetic nephropathy are unsurprisingly legion." | ( Goldsmith, DJ; Hajhosseiny, R; Jivraj, N; Khavandi, K; Malik, RA; Mashayekhi, S, 2014) |
| "Diabetic nephropathy is a complication of diabetes and a major cause of end-stage renal disease." | ( Hamar, P; Holthöfer, H; Hyvönen, ME; Kerjaschki, D; Koskelainen, S; Koskenniemi, K; Lehtonen, E; Lehtonen, S; Musante, L; Nyman, TA; Révész, C; Szalay, C; Tienari, J; Vaheri, A; Varmanen, P; Wasik, AA, 2014) |
| "Diabetic nephropathy is a major complication in diabetes and a leading cause of end-stage renal failure." | ( Fujitaka, K; Fukunari, A; Hirohashi, Y; Iguchi, T; Kakimoto, T; Kato, T; Kawai, M; Nishio, M; Okada, K; Relator, R; Utsumi, H, 2014) |
| "Diabetic nephropathy is the kidney disease that occurs as a result of diabetes." | ( Ashokkumar, N; Kandasamy, N, 2014) |
| "Diabetic nephropathy is a leading cause of end-stage renal disease worldwide." | ( Cazenave, M; Gauthier, M; Gueutin, V; Izzedine, H, 2014) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease in humans in the Western world." | ( Bartaun, C; Gembardt, F; Hohenstein, B; Hugo, C; Jarzebska, N; Mayoux, E; Todorov, VT, 2014) |
| "Diabetic nephropathy is characterized by a long clinically silent period without signs or symptoms of disease." | ( Bjornstad, P; Cherney, D; Maahs, DM, 2014) |
| "Diabetic nephropathy is a serious complication of diabetes mellitus with a pressing need for effective metabolic markers to detect renal impairment." | ( Chang, HH; Choong, B; Loomes, KM; Phillips, AR, 2015) |
| "Diabetic kidney disease is the leading cause of end-stage renal disease." | ( Márquez, E; Pascual, J; Riera, M; Soler, MJ, 2015) |
| "Diabetic nephropathy is a major cause of morbidity and mortality in diabetic patients." | ( Guan, GJ; Nie, HB; Sun, LN; Wang, XL; Zhao, L, 2014) |
| "Diabetic nephropathy is a major cause of end-stage kidney disease, and overactivity of the endocannabinoid/cannabinoid 1 receptor (CB1R) system contributes to diabetes and its complications." | ( Cinar, R; Earley, BJ; Godlewski, G; Jourdan, T; Ju, C; Kunos, G; Liu, J; Liu, Z; Pacher, P; Rosenberg, AZ; Szanda, G; Tam, J, 2014) |
| "Diabetic nephropathy is characterized by diffuse mesangial matrix expansion and is largely dependent on the TGF-β/Smad signaling pathway." | ( Miyamoto, S; Sharma, K; You, YH; Zhao, J, 2015) |
| "Diabetic nephropathy is one of the most common causes of end-stage kidney disease." | ( El-Moselhy, MA; Hofni, A; Khalifa, MM; Taye, A, 2014) |
| "Diabetic nephropathy is a complex disease that involves increased production of free radicals which is a strong stimulus for the release of pro-inflammatory factors." | ( Ayepola, OR; Brooks, NL; Cerf, ME; Oguntibeju, OO, 2014) |
| "Diabetic nephropathy is a long-standing microvascular complication of diabetes mellitus and is the leading cause of end stage renal disease in developed countries." | ( Cherney, DZ; Lytvyn, Y; Perkins, BA, 2015) |
| "Diabetic nephropathy is the most common cause of end-stage renal disease in patients with diabetes." | ( Lee, MK; Liu, B; Liu, K; Lu, C; Lv, G; Lv, X; Wu, Y; Xu, H, 2015) |
| "Diabetic nephropathy is one of the most important complications of both type 1 and type 2 diabetes." | ( Bozkurt, MF; Hazman, Ö, 2015) |
| "Diabetic nephropathy is the most common pathological disorder predisposing patients to end-stage renal disease." | ( Hinamoto, N; Maeshima, Y; Makino, H; Nasu, T; Sakai, Y; Sugiyama, H; Tanabe, K; Ujike, H; Watatani, H; Yamasaki, H, 2015) |
| "Diabetic nephropathy is a serious microvascular complication for patients associated with diabetes mellitus." | ( Barua, CC; Bodduluru, LN; Gogoi, R; Kasala, ER; Kolati, SR; Lahkar, M; Mahareddy, JR; Uppulapu, SK, 2015) |
| "Diabetic nephropathy is a major cause of morbidity and mortality among young adults with type 1 diabetes mellitus (DM)." | ( Abd El Shaheed, S; El-Mougy, FA; Hafez, MH; Makar, SH, 2015) |
| "Diabetic nephropathy is the major cause of kidney failure." | ( Adamíková, A, 2015) |
| "Diabetic nephropathy is characterized at its onset by glomerular hyperfiltration." | ( Bray, GA; Covington, JD; Johannsen, DL; Ravussin, E; Redman, LM, 2015) |
| "Diabetic nephropathy is a progressive kidney disorder and is pathologically characterized by thickened glomerular and tubular basement membranes, accumulation of the extracellular matrix and increased mesangial hypertrophy." | ( Ding, HH; Ni, WJ; Tang, LQ, 2015) |
| "Early stage diabetic nephropathy is characterized by glomerular hyperfiltration and reduced renal tissue Po2." | ( Fasching, A; Franzén, S; O'Neill, J; Palm, F; Patinha, D; Pihl, L, 2015) |
| "Diabetic nephropathy is a major cause of end-stage kidney disease." | ( Cagan, RL; Na, J; Park, AS; Susztak, K; Sweetwyne, MT, 2015) |
| "Diabetic nephropathy is the major cause of end-stage renal disease in Western societies." | ( Cooper, ME; Coughlan, MT; Ekinci, EI; Jerums, G; Sourris, KC; Yao, H, 2016) |
| "Backgroud: Diabetic nephropathy is one of the most frequent causes of end-stage renal disease and is associated with proliferation of glomerular mesangial cells (MCs) and excessive production of the extracellular matrix (ECM)." | ( Guan, MP; Li, WQ; Lyv, FP; Pang, RY; Wang, D; Xue, YM; Zheng, ZJ, 2015) |
| "Although diabetic nephropathy is associated with classic risk factors, early initiation of intensive treatment should be a priority in order to prevent worsening renal function." | ( Bonal, J; Bonet, J; Romero, R; Salinas, I; Sanmartí, A; Torres, F; Troya, MI, 2016) |
| "The pathogenesis of diabetic nephropathy is complex, and oxidative stress plays an important role in the development of diabetic nephropathy." | ( Ding, Y; Li, GH; Mi, N; Wang, WD; Xian, HX; Xu, J; Zhang, XJ, 2015) |
| "Diabetic nephropathy is one of the most serious complications of diabetes and is closely correlated with end-stage renal disease." | ( Cao, H; Fu, R; Ji, Y; Li, W; Liu, Y; Xiang, M, 2015) |
| "Diabetic nephropathy is one of the major microvascular complications of diabetes." | ( Bao, Y; Chen, H; Guo, K; Jia, W; Kou, J; Lu, J; Wu, M; Yu, H; Zhang, L; Zhang, M, 2015) |
| "Diabetic nephropathy is rapidly becoming the major cause of end-stage renal disease and cardiovascular mortality worldwide." | ( Khan, SS; Quaggin, SE, 2015) |
| "Diabetic nephropathy is one of the most common chronic complications of diabetes with poor efficacy of clinical treatment." | ( He, T; Ji, Y; Lv, W; Wang, J; Zhang, Q, 2016) |
| "Diabetic nephropathy is the most common cause of chronic kidney disease in the Western world." | ( Bakker, SJ; Frenay, AR; Hillebrands, JL; Lambers Heerspink, HJ; Pasch, A; van den Born, JC; van Goor, H, 2016) |
| "Diabetic nephropathy is a serious complication of type 2 diabetes mellitus, and delaying the development of diabetic nephropathy in patients with diabetes mellitus is very important." | ( Choi, R; Chung, CH; Kim, BH; Kim, HS; Lee, ES; Lee, EY; Lee, MY; Nawaboot, J, 2016) |
| "Early diabetic nephropathy is largely undetectable before substantial functional changes have occurred." | ( Bertelsen, LB; Laustsen, C; Mikkelsen, E; Nielsen, PM; Nørlinger, TS; Qi, H; Stødkilde Jørgensen, H; Xu, Y, 2016) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease." | ( Cai, L; Chen, X; Epstein, PN; Gu, J; Kong, L; Kong, M; Liang, G; Miao, L; Tan, Y; Wu, H; Zeng, J, 2016) |
| "Diabetic nephropathy is associated with aberrant glomerular filtration of serine proteases." | ( Andersen, H; Bistrup, C; Hansen, PB; Henriksen, JE; Jensen, BL; Nielsen, F, 2016) |
| "Since diabetic nephropathy is one of the complications of longterm diabetes, renal function was characterized in the STZ-rat model." | ( Bedenik, J; Grempler, R; Luippold, G; Voigt, A, 2016) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease worldwide, but no effective therapeutic strategy is available." | ( Ha, H; Jeong, BY; Lee, HB; Lee, JH; Miyata, T; Park, JH; Uddin, MJ, 2016) |
| "It is known that diabetic nephropathy is induced, to a large extent, by hyperglycemia." | ( Elmas, O; Erbas, O; Yigitturk, G, 2016) |
| "Early prevention of diabetic nephropathy is not successful as early interventions have shown conflicting results, partly because of a lack of early and precise indicators of disease development." | ( Bilous, R; Chaturvedi, N; de Zeeuw, D; Fuller, J; Klein, R; Lambers Heerspink, H; Lindhardt, M; Mischak, H; Orchard, T; Parving, HH; Persson, F; Porta, M; Rossing, P; Stalmach, A; Zürbig, P, 2017) |
| "Diabetic nephropathy is a serious microvascular complication and one of the main causes of end-stage renal disease." | ( Kaspate, D; Sadar, S; Vyawahare, N, 2016) |
| "Diabetic nephropathy is derived from long-term effects of high blood glucose on kidney function in type 2 diabetic patients." | ( Chiang, HS; Deng, WP; Dubey, NK; Leu, SJ; Li, WS; Liu, MC; Shieh, YH; Tsai, FC; Yu, SH, 2016) |
| "Diabetic nephropathy is a severe complication of Type 2 diabetes." | ( Bob, F; Dumitrascu, V; Gadalean, F; Gluhovschi, C; Gluhovschi, G; Jianu, DC; Matusz, P; Petrica, L; Popescu, R; Secara, A; Simulescu, A; Ursoniu, S; Velciov, S; Vlad, A; Vlad, D; Vlad, M, 2017) |
| "Diabetic nephropathy is one of the major microvascular complications of diabetes mellitus which ultimately gives rise to cardiovascular diseases." | ( Ahmed, S; Borgohain, MP; Choubey, A; Chowdhury, L; Kumar, S; Lahkar, M; Pant, R, 2017) |
| "Diabetic kidney disease is the leading cause of end-stage renal disease, a significant contributor to cardiovascular (CV) disease, responsible for much of the morbidity and mortality in patients with type 2 diabetes (T2DM)." | ( Avogaro, A; Fioretto, P, 2017) |
| "Diabetic Nephropathy is one of the leading causes of death in diabetic patient." | ( Ahirwar, AK; Bherwani, S; Ghotekar, LH; Jibhkate, SB; Patel, S; Prajapat, B; Sandhya, AS; Saumya, AS; Singh, R, 2017) |
| "Diabetic nephropathy is one of the most important complications in patients with diabetes mellitus." | ( Eisenreich, A; Leppert, U, 2017) |
| "Diabetic nephropathy is one of the most frequent, devastating and costly complications of diabetes." | ( Hasan, AA; Hocher, B, 2017) |
| "Diabetic nephropathy is one of the leading causes of end-stage renal disease." | ( Chen, IW; Chen, ST; Chiu, DT; Chou, CA; Lin, CN, 2018) |
| "Diabetic nephropathy is the leading cause of kidney failure." | ( Toto, RD, 2017) |
| "Diabetic Kidney Disease is associated with excessive mortality and morbidity." | ( Fridell, J; Moinuddin, I; Powelson, J; Sharfuddin, A; Taber, T; Yaqub, MS, 2018) |
| "Diabetic nephropathy is one of the most important microvascular complications of diabetes mellitus and is responsible for 40-50% of all cases of end stage renal disease." | ( Bertram, A; Haller, H; Ji, L; Menne, J; Stahl, K, 2017) |
| "Diabetic nephropathy is a common complication of diabetes, but there are currently few treatment options." | ( Duan, W; Gao, L; Lei, M; Liao, Z; Liu, L; Liu, T; Nizigiyimana, P; Xu, B, 2018) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease and is associated with high-cardiovascular risk and significant morbidity and mortality." | ( Tahara, A; Takasu, T, 2018) |
| "Background Diabetic nephropathy is the leading cause of end-stage renal disease." | ( Navale, AM; Paranjape, A, 2018) |
| "Diabetic nephropathy is the final stage of renal complications caused by diabetes and for its treatment there are few alternatives." | ( García-López, P; Granados-Pineda, J; Pérez-Rojas, JM; Ramos-Godinez, MDP; Rivero-Cruz, JF; Uribe-Uribe, N, 2018) |
| "Diabetic kidney disease is a renal microvascular disease caused by diabetes, known as one of the most serious and lethal complications of diabetes." | ( Jia, YJ; Wang, Y; Xue, YM; Yang, YL; Zheng, ZJ, 2018) |
| "Diabetic nephropathy is one of the serious complications of diabetes mellitus." | ( Abediazar, S; Abroon, S; Akbarian, N; Amanzadeh, M; Bannazadeh Baghi, H; Darbin, A; Mihanfar, A; Mota, A; Rahmati-Yamchi, M; Zarghami, N, 2018) |
| "Diabetic nephropathy is one of the manifestations of systemic microangiopathy in diabetes." | ( Guo, F; Li, Z; Qin, G; Wang, B; Zhang, Y, 2018) |
| "Diabetic nephropathy is characterised by the excessive amount of extracellular matrix in glomeruli and tubulointerstitial space." | ( Gill, A; Pollock, CA; Saad, S; Schilter, HC; Stangenberg, S; Wong, MG; Zaky, A, 2018) |
| "Diabetic nephropathy is the commonest cause of end-stage renal disease and affects between 30 and 45% of patients with diabetes mellitus." | ( Fouli, GE; Gnudi, L, 2019) |
| "Nodular glomerulosclerosis is a characteristic histological finding of diabetic nephropathy (DN) with thickened glomerular basement membrane and hyalinized arterioles." | ( Anand, M; Fülöp, T; Hamrahian, M; Mollaee, M, 2018) |
| "Diabetic nephropathy is one of the most common and serious complications of diabetes mellitus." | ( Dong, Y; Guo, C; Liu, Y; Xie, G; Zhu, H, 2018) |
| "*Diabetic nephropathy is a common complication of diabetes mellitus and one of the major etiologies of end-stage renal disease." | ( Ahamad, SR; Ahmad, A; Alkharfy, KM; Ansari, MA; Jan, BL; Mohsin, K; Raish, M, 2017) |
| "Diabetic nephropathy is a common complication of diabetes." | ( Liu, J; Tian, H; Xie, Z; Yang, J, 2018) |
| "Diabetic nephropathy is the commonly developed complication of vasculature in type 2 diabetic patients." | ( Kulkarni, YA; Oza, MJ, 2019) |
| "Diabetic kidney disease is a serious complication of diabetes that can ultimately lead to end-stage renal disease." | ( Bergman, HM; Kihlberg, J; Lanekoff, I; Lindfors, L; Palm, F, 2019) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease." | ( Chang, PJ; Chiang, WC; Hsu, YC; Huang, YT; Lin, CL; Shih, YH; Wang, CJ, 2019) |
| "Diabetic kidney disease is a major cause of renal failure that urgently necessitates a breakthrough in disease management." | ( Abe, T; Akiyama, Y; Asaji, K; Breeggemann, MC; Fukuda, NN; Fukuda, S; Heymann, J; Ho, HJ; Hozawa, A; Ichijo, M; Ito, S; Iwasaki, T; Kanemitsu, Y; Kikuchi, K; Kopp, JB; Kure, S; Mano, N; Matsuhashi, T; Matsumoto, Y; Matsuo, A; Mise, K; Mishima, E; Mukawa, C; Nagao, S; Nakamura, T; Nanto-Hara, F; Oe, Y; Ogata, Y; Ogawa, S; Ogura, J; Ohsaki, Y; Oikawa, Y; Owada, Y; Saigusa, D; Saito, R; Sato, T; Shima, H; Shimada, S; Shimizu, M; Soga, T; Suzuki, C; Suzuki, N; Suzuki, T; Takahashi, N; Thanai, P; Tomioka, Y; Toyohara, T; Tsukamoto, H; Tsukimi, T; Wada, J; Wada, T; Yamaguchi, H; Yamamoto, M; Yang, CC, 2019) |
| "Diabetic nephropathy is one of the dreaded complications of diabetes leading to chronic kidney disease and end stage renal failure globally." | ( Dhakal, SP; Nepal, SP; Parajuli, S; Paudel, BD; Sah, AK; Thakur, SK, 2019) |
| "Diabetic nephropathy is the most serious complication of diabetes." | ( Gao, M; Huang, YP; Jiang, CH; Liu, Y; Lou, DX; Pan, K; Yin, ZQ; Zhang, J; Zhang, XX, 2019) |
| "Diabetic kidney disease is a major complication in diabetes mellitus, and the most common reason for end-stage renal disease." | ( Bork, T; Huber, TB; Kaminski, MM; Kammerer, B; Lagies, S; Lienkamp, SS; Pichler, R; Troendle, K; Walz, G; Zimmermann, S, 2019) |
| "Diabetic kidney disease is a growing problem leading to end-stage kidney disease but also atherosclerotic cardiovascular disease and heart failure." | ( Frimodt-Møller, M; Persson, F; Rossing, P, 2020) |
| "Diabetic kidney disease is one of these complications that represent the main cause of end-stage renal disease in Western countries." | ( Di Vincenzo, A; El Hadi, H; Pagano, C; Rossato, M; Tana, C; Vettor, R, 2019) |
| "Diabetic nephropathy is a major complication of hyperglycemia." | ( Choi, KM; Yoo, HS, 2019) |
| "Diabetic nephropathy is the most common long-term complication of diabetes mellitus." | ( Ahmad, N; Ai, J; Al-Azab, M; Li, X; Niu, M; Shopit, A; Tang, Z; Tesfaldet, T; Wang, H, 2020) |
| "Diabetic nephropathy is characterized by the chronic loss of kidney function due to high glucose renal levels." | ( Benito-Martínez, S; Bernardo-Bermejo, S; Castro-Puyana, M; Lucio-Cazaña, FJ; Marina, ML; Sánchez-López, E, 2020) |
| "Diabetic kidney disease is a worldwide epidemic, and therapies are incomplete." | ( Balogh, DB; Besztercei, B; Fekete, A; Genovese, F; Hodrea, J; Hosszu, A; Koszegi, S; Lenart, L; Sparding, N; Szabo, AJ; Wagner, LJ, 2020) |
| "Diabetic nephropathy is one the most serious diabetic microangiopathies, which is the main cause of mortality in diabetic patients." | ( Bai, J; Gong, B; Gou, X; Han, T; Ji, X; Qi, Y, 2020) |
| "Diabetic nephropathy is the kidney disease that occurs as a result of diabetes." | ( Hiratani, K; Natazuka, T; Park, CH; Yokozawa, T, 2020) |
| "Diabetic nephropathy is a diabetic complication caused by chronic inflammation." | ( An, X; Cao, Y; Chen, J; Qin, H; Yang, L; Zhang, Y, 2020) |
| "Diabetic kidney disease is one of the fastest growing causes of death worldwide." | ( Carriazo, S; Fernandez-Fernandez, B; Fontecha-Barriuso, M; Goma-Garces, E; Guerrero-Mauvecin, J; Martin-Sanchez, D; Martinez-Moreno, JM; Ortiz, A; Ramos, AM; Ruiz-Ortega, M; Sanchez-Niño, MD; Sanz, AB, 2020) |
| "Diabetic nephropathy is the principal cause of end-stage renal failure and current interventions for its recession remains unsatisfactory." | ( Habib, HA; Heeba, GH; Khalifa, MMA, 2021) |
| "Diabetic nephropathy is the leading cause of renal failure worldwide." | ( Ding, C; Li, L; Liang, G; Qian, J; Xiong, Z; Xu, M; Zhang, A; Zhu, W; Zou, C, 2020) |
| "Diabetic nephropathy is a major cause of chronic kidney disease and end-stage renal failure worldwide." | ( El Fayoumi, HM; Elkazzaz, SK; Khodeer, DM; Moustafa, YM, 2021) |
| "Diabetic nephropathy is the leading cause for end-stage renal disease worldwide." | ( Harloff, M; Prüschenk, S; Schlossmann, J; Seifert, R, 2022) |
| "Diabetic nephropathy is a lethal disease that can lead to chronic kidney disease and end-stage kidney disease." | ( Fang, J; Hu, M; Liu, D; Liu, Z; Pan, S; Xing, G; Zhou, S, 2021) |
| "Diabetic kidney disease is the leading cause of end-stage kidney disease in high-income countries." | ( D'Addio, F; De Salvo, C; Fiorina, P; Gallieni, M; Lunati, ME; Miglio, R; Pastore, I; Rossi, A; Sabiu, G; Zuccotti, GV, 2021) |
| "Diabetic nephropathy is a serious complication of diabetes." | ( Bao, J; Lou, Y; Sun, X; Yu, J; Zhang, S; Zhou, J, 2021) |
| "Diabetic nephropathy is reported to occur as a result of the interactions between several pathophysiological disturbances, as well as renal oxidative stress and inflammation." | ( Abu Bakar, AB; Jalil, NAC; Mohamed, M; Nna, VU; Othman, ZA; Zakaria, Z, 2021) |
| "Diabetic nephropathy is a common complications related to high morbidity and mortality in type 2 diabetes." | ( Barnett, SD; Hammock, BD; Hwang, SH; Imig, JD; Jankiewicz, WK; Khan, MAH; Stavniichuk, A, 2021) |
| "Diabetic nephropathy is highly correlated with the occurrence of other complications of type 1 diabetes (T1D) and type 2 diabetes (T2D) mellitus; for example, hypertension with cardiovascular disease (CVD) being the most frequent cause of death in patients with end-stage renal disease and undergoing renal dialysis." | ( Accili, D; Arduini, A; Bonomini, M; Davies, SJ; Lambie, M; Zammit, V, 2021) |
| "Diabetic nephropathy is a kidney disease caused by long-term hyperglycemia." | ( Bu, S; Chu, Y; Dai, H; Hu, F; Hu, P; Qiu, X; Sha, W; Yang, X, 2021) |
| "Diabetic nephropathy is glomerular sclerosis caused by diabetic microvascular disease, which is one of the most serious complications of diabetes." | ( Bao, P; Liu, L; Nan, Z; Yu, Z; Zhang, Y; Zhu, Z, 2021) |
| "Diabetic kidney disease is a microvascular complication that occurs in patients with diabetes." | ( Bielka, W; Pawlik, A; Przezak, A, 2021) |
| "Diabetic nephropathy is one of the most important and growing diseases globally and the leading cause of cardiovascular mortality in these patients." | ( Jia, S; Ma, J; Yang, R; Yang, Z, 2022) |
| "Diabetic nephropathy is a common complication of the kidneys induced by diabetes and is the main cause of end-stage renal disease." | ( Li, Z; Liu, M; Miao, Y; Shi, R; Wang, Y; Xue, X; Yang, Y, 2022) |
| "The development of diabetic nephropathy is aided by the presence of oxidative stress." | ( Arockiaraj, J; Guru, A; Issac, PK; Pachaiappan, R; Sudhakaran, G; Velayutham, M, 2022) |
| "Diabetic nephropathy is one of the common complications of diabetes mellitus, which seriously affects the life quality and health of patients." | ( Chen, Q; Fei, X; Gao, C; Wang, M; Zhao, N, 2022) |
| "Diabetic nephropathy is a serious chronic complication affecting at least 25% of diabetic patients." | ( Chen, RJ; Day, CH; Ho, TJ; Hsieh, DJ; Huang, CY; Kuo, CH; Kuo, WW; Lai, CH; Lin, CY; Lin, YC; Paul, CR; Shibu, MA; Shih, TC, 2022) |
| "Diabetic kidney disease is a major cause of global end-stage renal diseases." | ( Geng, J; Gu, W; Guan, Y; Hou, X; Li, X; Song, G; Wang, C; Wang, X; Yang, L; Zheng, K, 2022) |
| "Diabetic nephropathy is one of the chronic microvascular complications of diabetes and is a leading cause of end-stage renal disease." | ( Li, N; Zhou, H, 2022) |
| "Diabetic kidney disease is an important diabetic complication as a causative disease for the progression of dialysis." | ( Kojima, N, 2022) |
| "Diabetic nephropathy is one of the major diabetic complications which has become the major cause of end-stage renal disease." | ( Li, S; Piao, F; Wang, D; Zhang, C; Zhang, M, 2022) |
| "Diabetic kidney disease is one of the long-term microvascular complications of diabetes." | ( Netere, AK; Sendekie, AK, 2022) |
| "Diabetic nephropathy is one of the leading causes of end-stage renal disease worldwide." | ( Ardjmand, A; Ghavipanjeh, G; Jozi, F; Kheiripour, N; Nasehi, Z; Shahaboddin, ME; Taheri, MA, 2022) |
| "Diabetic kidney disease is the main cause of end-stage renal disease worldwide." | ( Hirakawa, Y; Inagi, R; Kojima, K; Nangaku, M; Shibahara, T; Wada, T; Yamashita, Y; Yoshioka, K, 2022) |
| "Diabetic kidney disease is one of the most serious complications of diabetes, which leads to serious psychological and economic burdens to patients and society when it progresses to end-stage renal disease." | ( Chen, Y; Wu, Y, 2022) |
| "Diabetic nephropathy is a common complication of diabetes mellitus and the leading cause of end-stage renal disease." | ( D'Alessandro, VF; D'Alessandro-Gabazza, CN; Fujimoto, H; Gabazza, EC; Inoue, C; Kobayashi, T; Nishihama, K; Okano, Y; Takeshita, A; Tharavecharak, S; Toda, M; Yano, Y; Yasuma, T, 2022) |
| "Diabetic nephropathy is a common complication of diabetes mellitus and the leading cause of end-stage renal disease." | ( D'Alessandro, VF; D'Alessandro-Gabazza, CN; Fujimoto, H; Gabazza, EC; Inoue, C; Kobayashi, T; Nishihama, K; Okano, Y; Takeshita, A; Tharavecharak, S; Toda, M; Yano, Y; Yasuma, T, 2022) |
| "Diabetic nephropathy is a common complication of diabetes mellitus and the leading cause of end-stage renal disease." | ( D'Alessandro, VF; D'Alessandro-Gabazza, CN; Fujimoto, H; Gabazza, EC; Inoue, C; Kobayashi, T; Nishihama, K; Okano, Y; Takeshita, A; Tharavecharak, S; Toda, M; Yano, Y; Yasuma, T, 2022) |
| "Diabetic nephropathy is manifested in more than 10% of people with diabetes." | ( Sahakyan, G; Sahakyan, N; Vejux, A, 2022) |
| "Diabetic nephropathy is the leading cause of end-stage renal failure, but the effectiveness of currently available strategies for preventing diabetic nephropathy remains unsatisfactory." | ( Aftab, U; Akhtar, T; Ashraf, A; Shabbir, A; Shahzad, M, 2023) |
| "Diabetic nephropathy is one of the major complications of Type 2 diabetes mellitus." | ( Guldiken, S; Sipahi, T; Sut, N; Ustundag, S; Yukcu, F, 2023) |
| "Diabetic nephropathy is an unavoidable complication of chronic uncontrolled diabetes mellitus." | ( Aboubaker, EM; Ali, FEM; Hofni, A; Ibrahim, ARN, 2023) |
| "Diabetic nephropathy is a major microangiopathic complication of type 2 diabetes and a leading cause of chronic kidney disease (CKD)." | ( Kitov, S; Linev, A; Nikolov, D; Nikolov, G; Stoyanova, VK; Vladimirova-Kitova, L, 2022) |
| "Diabetic nephropathy is a leading cause of end-stage renal disease." | ( Abebe, EC; Adella, GA; Adugna, DG; Anley, DT; Bantie, B; Dejenie, TA; Dessie, AM; Feleke, SF; Gebeyehu, NA; Gebrekidan, AY; Gesese, MM; Kassie, GA; Kebede, YS; Mengstie, MA; Moges, N; Seid, MA; Tegegne, KD; Zemene, MA, 2023) |
| "Diabetic nephropathy is a multifactorial disease." | ( Abu Seman, N; Othman, SH, 2023) |
| "Diabetic nephropathy is one of the leading causes of end-stage renal disease worldwide." | ( Che, X; Gu, L; Lu, J; Lu, R; Min, L; Qian, C; Song, A; Wang, M; Xie, K, 2023) |
| "Diabetic kidney disease is an important microvascular complication of diabetes and the leading cause of end-stage renal disease." | ( Chen, YX; Fu, YQ; Hu, YM; Jiang, XX; Jin, CY; Jin, ZS; Xu, CQ; Zhang, BL; Zhang, QY, 2023) |
| "Diabetic Kidney Disease is one of the most relevant complications and affects approximately one-third of patients with Diabetes Mellitus." | ( Araujo, AC; Barbalho, SM; de Oliveira E Silva Ullmann, T; Flato, UAP; Guiguer, EL; Laurindo, LF; Ramalho, BJ; Rubira, CJ; Sloan, KP; Tofano, RJ, 2023) |
| "The burden of diabetic nephropathy is high in the T2DM patients attending our clinic and this is linked with advancing age." | ( Fasanu, AN; Ikem, RT; Kolawole, BA; Lawal-Bello, AT; Soyoye, DO, 2023) |
| "Diabetic nephropathy is one of the most important microvascular complications of diabetes, which mainly refers to glomerular capillary sclerosis." | ( Cao, X; Hou, SZ; Li, Y; Zhang, M; Zhao, MC; Zhao, TQ, 2023) |
| "Type 2 diabetic nephropathy is a common diabetic complication and the main cause of death in patients with diabetes." | ( Huang, X; Kong, J; Li, X; Wang, X; Wu, H; Xu, F; Yang, X; Yu, P; Zhang, L; Zhen, C, 2023) |
| "Diabetic nephropathy is a major complication of diabetes mellitus and is related to dysfunction of renal cells." | ( Jiang, H; Ma, W; Yang, G; Yang, W; Yi, Q, 2023) |
| "Diabetic kidney disease is associated with impaired podocyte autophagy and subsequent podocyte injury." | ( 't Hart, DC; Delbet, JD; Dionet, L; Karras, A; Lenoir, O; Letavernier, E; Mahtal, N; Nijenhuis, T; Rabant, M; Saito, R; Salemkour, Y; Tharaux, PL; van der Vlag, J; Verheijden, KAT; Yildiz, D, 2023) |
| "Diabetic nephropathy is one of the most significant complications of diabetes, resulting in increased patient mortality." | ( Liu, C; Ni, P; Song, Y; Tang, M; Zhang, Z; Zhao, B, 2023) |
| Excerpt | Reference |
|---|
| "The difference in the progression of diabetic nephropathy during and after pregnancy can be explained by increased hypertension during pregnancy, especially in the third trimester, despite an intensified antihypertensive therapy." | ( Biesenbach, G; Stöger, H; Zazgornik, J, 1992) |
| "In incipient diabetic nephropathy, therapy with CEI but not CCB tends to reduce filtration fraction, especially in hyperfiltering patients." | ( Allen, TJ; Cooper, ME; Jerums, G; Tsalamandris, C, 1992) |
| "Latent diabetic nephropathy with no complication such as retinopaty and hypertension was treated with Alacepril, an ACE inhibitor." | ( Hashimoto, T, 1991) |
| "In conclusion, in patients with diabetic nephropathy who have to initiate dialysis treatment, uremic symptoms have progressed though serum creatinine levels are relatively low." | ( Nakao, T, 1990) |
| "To explore a possible link between diabetic nephropathy and the enhanced activity of the polyol pathway known to occur in diabetes, we examined several pertinent metabolic parameters in glomeruli isolated from control and streptozotocin-diabetic rats and assessed whether changes observed in diabetic glomeruli could be prevented by the oral administration of the aldose reductase inhibitor sorbinil." | ( Cohen, MP, 1986) |
| "Nine patients with overt diabetic nephropathy underwent renal scintigraphy and measurement of platelet survival time using indium-111-labelled platelets after treatment for six weeks with aspirin-dipyridamole (990 mg/225 mg/day) or placebo in a double-blind cross-over study." | ( Barker, MJ; Davies, JA; Hooper, AH; Spencer, AA; Stainton, C; Tindall, H, 1986) |
| "Only in the case of diabetic nephropathy is there yet reasonable evidence of antihypertensive treatment reducing the rate of progression of the disease." | ( Drury, PL, 1983) |
| "Five patients with severe diabetic nephropathy (SN) and six patients with moderate diabetic nephropathy (MN) have been treated with intraperitoneal (i." | ( Hanover, B; Jacobsen, SC; Kablitz, C; Maxwell, JG; Stephen, RL; Tyler, F, 1983) |
| "A 62-year-old Indian with diabetic nephropathy controlled with metformin, developed miliary tuberculosis for which he was treated with rifampicin, isoniazid and ethambutol." | ( Beckett, AG; Dandona, P; Greenbury, E, 1980) |
| "In 47 patients with diabetic nephropathy (29 type I, 18 type II) renal function and blood pressure (BP) (treated with or without an angiotensin-converting enzyme [ACE] inhibitor, enalapril [10 mg], in 38 hypertensive patients) were followed over 4 years." | ( Hewitson, TD; Martin, FI; Nolan, CJ; Taft, JL; Yeung, SP, 1994) |
| "The present data suggest that in diabetic nephropathy: (1) intrarenal coagulation is likely to occur and to induce progression of renal dysfunction; and (2) heparin therapy could be effective in diabetic nephropathy when the patients are selected according to the above parameters of coagulation and fibrinolysis." | ( Eto, S; Hashimoto, O; Kaizu, K; Morita, E; Suzuki, H; Uriu, K, 1993) |
| "We assessed the prognosis of diabetic nephropathy during long-term antihypertensive treatment as compared to the prognosis during the natural history of this complication in a prospective study of all IDDM patients (N = 45) aged under 50 with onset of diabetes before the age of 31 who developed diabetic nephropathy between 1974 and 1978 at Steno Diabetes Center, and were followed until death or for at least 16 years [median 16 (4 to 21) years]." | ( Hommel, E; Jacobsen, P; Parving, HH; Rossing, K; Rossing, P; Smidt, UM, 1996) |
| "In normotensive patients with incipient diabetic nephropathy low-dose administration of enalapril, nitrendipine and placebo does not result in clear cut differences in albuminuria." | ( Bender, R; Berger, M; Heinemann, L; Janicke, I; Sawicki, PT, 1996) |
| "We conclude that in patients with diabetic nephropathy addition of AT1a therapy to ACEi therapy attenuates AngII effects better than ACEi therapy alone." | ( Cosio, FG; Falkenhain, ME; Hebert, LA; Nahman, NS; O'Dorisio, TM, 1999) |
| "The prognosis of diabetic nephropathy has improved during the past decades, predominantly because of effective antihypertensive treatment." | ( Hovind, P; Parving, HH; Rossing, P; Smidt, UM; Tarnow, L, 2001) |
| "In the treatment of diabetic nephropathy, ACE inhibitor therapy reduces albumin excretion and slows the rate of decline in glomerular filtration rate (GFR)." | ( , 2001) |
| "Furthermore, the phenotypes of advanced diabetic nephropathy were prevented by administering an AGE inhibitor, (+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide (OPB-9195), thus establishing the AGE-RAGE system as a promising target for overcoming this aspect of diabetic pathogenesis." | ( Doi, T; Kato, I; Ohashi, S; Okamoto, H; Sakurai, S; Takasawa, S; Takeuchi, M; Watanabe, T; Yamagishi, S; Yamamoto, H; Yamamoto, Y; Yonekura, H, 2001) |
| "Many patients with diabetic nephropathy (DN) have levels of albuminuria > 1 g/day and blood pressure >135/85 mmHg, despite antihypertensive combination therapy, including recommended doses of ACE inhibitors, e." | ( Christensen, PK; Jensen, BR; Parving, HH; Rossing, K, 2002) |
| "Seventy-six patients with type-2 diabetic nephropathy, who had normal renal function tests were randomized into the 4 groups; each group (n = 19) received one of the following treatments: aspirin (1000 mg), dipyridamole (750 mg), their combination or placebo daily for 2 months." | ( Khajehdehi, P; Mostafavi, H; Roozbeh, J, 2002) |
| "In type 2 diabetic patients with diabetic nephropathy, 6 months of treatment with low dose valsartan, an angiotensin-II receptor antagonist, thus reduced UAE with no reduction in systemic blood pressure." | ( Aizawa, Y; Ikarashi, T; Kaneko, S; Nakagawa, O; Souda, S; Suzuki, K, 2002) |
| "The clinical course of patients with diabetic glomerulosclerosis, IgA nephropathy, crescentic glomerulonephritis, and MPO-ANCA seropositivity seems to resemble that of ANCA-associated, rapidly progressive glomerulonephritis and is potentially amenable to aggressive immunosuppressive therapy." | ( Chan, KW; Chan, TM; Lai, KN; Lo, WK; Lui, SL; Yip, PS, 2002) |
| "Once the patient of diabetic nephropathy reaches the end stage renal disease, renal replacement therapy is needed." | ( Agarwal, DK, 2002) |
| "The total of 136 early diabetic nephropathy patients were randomly divided into two groups, 50 cases in the conventional treated group and 86 in the AI treated group, the therapeutic course being 3 weeks." | ( Li, QZ; Liu, ZQ; Qin, GJ, 2001) |
| "Prevention or retardation of diabetic nephropathy (DN) includes anti-hypertensive treatment with angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II type 1 receptor blockers (ARB) on the premises that these drugs have an added protective effect beyond their influence on BP." | ( Inagi, R; Ishikawa, N; Koike, H; Kurokawa, K; Miyata, T; Mizuno, M; Nangaku, M; Sada, T; Ueda, Y; van Ypersele de Strihou, C; Yuzawa, H, 2003) |
| "Therefore, prevention and treatment of diabetic nephropathy has become a prominent goal in the treatment of patients with diabetes mellitus." | ( Jungmann, E, 2003) |
| "The main goal in the treatment of diabetic nephropathy is control of the glycaemic status and aggressive antihypertensive therapy, primarily with RAAS-blocking agents." | ( Mogyorósi, A; Sonkodi, S, 2003) |
| "In 22 patients with type 2 diabetes and diabetic nephropathy in stages 3-5, treatment with the ACEI lisinopril was initiated." | ( Amann, B; Angelkort, B; Tinzmann, R, 2003) |
| "Fifty-seven patients with diabetic nephropathy were divided equally into group A with treatment with losartan (50 mg) and fosinopril (10 mg) daily, group B with daily losartan treatment (50-100 mg), and group C with fosinopril treatment at the daily dose of 10-20 mg." | ( Huang, YH; Shen, W; Wang, HT; Wang, Y; Zhang, H; Zhu, QZ, 2003) |
| "In the Irbesartan in Diabetic Nephropathy Trial (IDNT), treatment with irbesartan demonstrated 23 and 20% reductions in the combined endpoint of doubling of serum creatinine (DSC), end-stage renal disease (ESRD) or death in patients with hypertension, type 2 diabetes and overt nephropathy compared with amlodipine and control, respectively." | ( Annemans, L; Cordonnier, DJ; Lamotte, M; Palmer, AJ; Rodby, RA; Roze, S, 2003) |
| "The "Irbesartan in Diabetic Nephropathy Trial" (IDNT), demonstrated a reduction in the combined endpoint of doubling of serum creatinine, end-stage renal disease (ESRD) or death compared to control or amlodipine arms in patients with hypertension, type 2 diabetes and overt nephropathy when treated with irbesartan." | ( Annemans, L; Lamotte, M; Palmer, AJ; Ritz, E; Rodby, RA; Roze, S, 2004) |
| "Apoptosis occurs in diabetic nephropathy, involving tubular and interstitial cells, an effect reversed by insulin therapy." | ( Burns, KD; Kumar, D; Robertson, S; Zimpelmann, J, 2004) |
| "In the Irbesartan Diabetic Nephropathy Trial (IDNT), treatment with irbesartan demonstrated 23% and 20% reductions in the combined endpoint of doubling of serum creatinine (DSC), end-stage renal disease (ESRD) or death in patients with hypertension, type 2 diabetes and overt nephropathy compared to amlodipine and control respectively." | ( Annemans, L; de Alvaro, F; Lamotte, M; Palmer, AJ; Rodby, RA; Roze, S, 2004) |
| "Using FAM to treat 31 patients with diabetic nephropathy and controlled by 23 patients treated with Losartan, the therapeutic course was 3 months for both groups, changes of clinical symptoms, blood glucose, lipid metabolism and urinary albumin were observed and compared." | ( Chen, YP; Wang, HY, 2004) |
| "The study group consisted of 37 diabetic nephropathy patients treated with peritoneal dialysis." | ( Buraczynska, K; Koziol-Montewka, M; Ksiazek, A; Majdan, M; Tokarz, A, 2004) |
| "In patients with diabetic nephropathy, although urinary type IV collagen did not decrease after conventional treatment, it was significantly reduced by spironolactone." | ( Hayashi, K; Saruta, T; Sato, A, 2005) |
| "Although treatments for diabetic kidney disease are available, many patients still have progressive disease." | ( Tuttle, KR; Williams, ME, 2005) |
| "Rats with diabetic nephropathy were divided into four groups: untreated controls, and animals that received GTP (100 mg kg-1 body weight day-1), PHGG (100 mg kg-1 body weight day-1) and GTP plus PHGG (50 mg kg-1 body weight day-1 plus 50 mg kg-1 body weight day-1)." | ( Juneja, LR; Nakagawa, T; Okubo, T; Oya, T; Yokozawa, T, 2005) |
| "The irbesartan in Diabetic Nephropathy Trial (IDNT) demonstrated that treatment of patients with type 2 diabetes, hypertension and nephropathy with irbesartan resulted in a 20% relative reduction of the composite endpoint of doubling serum creatinine, end-stage renal disease or death as compared with amlodipine and placebo (antihypertensive standard therapy)." | ( Burnier, M; Frei, A; Hess, B; Palmer, AJ, 2006) |
| "In the treatment of diabetic nephropathy, the control of blood pressure, which has to be maintained near or below 130/80 mmHg associated to the blockade of the renin-angiotensin system with ACEIs or BRAs are the best strategies to promote renal and CV protection." | ( Zanella, MT, 2006) |
| "Twenty Caucasian patients with diabetic nephropathy and nephrotic range albuminuria (>2500 mg/24 h) despite recommended antihypertensive treatment completed this double-masked, randomized crossover trial." | ( Boomsma, F; Juhl, TR; Parving, HH; Rossing, K; Rossing, P; Schjoedt, KJ; Tarnow, L, 2006) |
| "To test its effects in diabetic nephropathy (DN), ALT-711 was administered (1 mg/kg daily i." | ( Basgen, J; Brem, H; Cai, W; Li, Z; Peppa, M; Uribarri, J; Vlassara, H; Zhang, JG, 2006) |
| "A 64-year-old male patient with diabetic nephropathy had been treated with maintenance hemodialysis therapy for 4 years, and had developed disturbed consciousness." | ( Iino, Y; Kaneko, T; Katayama, Y; Mii, A; Saito, SK; Takada, D; Tsuzuku, Y; Ueda, K; Utsumi, K, 2006) |
| "Overt diabetic nephropathy (n = 619) was defined as having an albumin excretion rate (AER) >200 microg/min or renal replacement therapy; incipient diabetic nephropathy was defined as having an AER of 20-200 microg/min (n = 336)." | ( Brismar, K; Dahlquist, G; Forsblom, C; Groop, PH; Marklund, SL; Möllsten, A; Parkkonen, M; Svensson, M; Wessman, M, 2007) |
| "We describe a patient with diabetic nephropathy and proteinuria who developed a remarkable hyperkalaemia on treatment with an angiotensin-receptor blocker." | ( Bolk, JH; Ijpelaar, DH; van Nieuwkoop, C, 2007) |
| "After 24 weeks of treatment, diabetic nephropathy and oxidative stress were assessed by biochemical analyses of urine and histological analyses of the kidneys." | ( Fukagawa, M; Hamada, Y, 2007) |
| "Using a type 1 diabetic nephropathy model that shows noticeable glomerulosclerosis, we examined the role of MCP-1/CCR2 by propagermanium (Pro; CCR2 antagonist) treatment, and confirmed it by transfection of plasmids carrying the 7ND (a mutant of MCP-1) gene." | ( Abe, H; Arai, H; Doi, T; Fukatsu, A; Iehara, N; Kanamori, H; Kita, T; Matsubara, T; Mima, A; Nagai, K; Okamoto, H; Sumi, E; Takahashi, T, 2007) |
| "The number of patients with diabetic nephropathy is also expected to increase considerably in the future despite currently available treatments that may prevent or slow kidney disease progression." | ( Anderson, PW; McGill, JB; Tuttle, KR, 2007) |
| "Treatments of diabetic nephropathy (DN) delay the onset of end-stage renal disease." | ( Bolton, WK; Degenhardt, TP; Khalifah, RG; McGill, JB; Schotzinger, RJ; Williams, ME, 2007) |
| "Current renoprotective treatments for diabetic nephropathy include strict glycemic and optimal blood pressure control, proteinuria/albuminuria reduction and the use of renin-angiotensin-aldosterone system (RAAS) blocking agents." | ( Cattaneo, D; Cortinovis, M; Perico, N; Remuzzi, G, 2008) |
| "Future strategies for therapy of diabetic nephropathy may therefore need to involve interception of both the TGF-beta and the VEGF signaling pathways to counter the matrix accumulation and to improve the albuminuria." | ( Ziyadeh, FN, 2008) |
| "Early stage of diabetic nephropathy was induced by administration of alloxan (150 mg/kg, I." | ( Bhatti, R; Mishra, A; Singh Ishar, MP; Singh, A, 2010) |
| "Sixty patients with early diabetic nephropathy were randomly assigned to the control group treated by benazepril alone, and the treated group treated by BC and benazepril, and the treatment lasted for 16 weeks." | ( Li, YH; Song, J; Yang, XD, 2009) |
| "The ideal treatment for diabetic nephropathy should slow the progress of renal failure, delay the initiation of dialysis, and protect residual renal function in patients receiving dialysis." | ( Jia, FY; Meng, JZ; Yuan, WJ, 2009) |
| "Furthermore, in the management of diabetic kidney disease in elderly patients, treatment with ACE inhibitors or ARBs is also recommended to reduce the risk or slow the progression of nephropathy." | ( Pappoe, LS; Winkelmayer, WC, 2010) |
| "Sixty-eight diabetic nephropathy patients with microalbuminuria were randomly allocated to 1 of 4 treatment groups: losartan 100 mg/day (group A), candesartan 12 mg/day (group B), olmesartan 40 mg/day (group C), or telmisartan 80 mg/day (group D)." | ( Fujiwara, N; Koide, H; Nakamura, T; Sato, E; Sugaya, T; Ueda, Y, 2010) |
| "A 75-year-old man with diabetic nephropathy treated with hemodialysis visited to a medical office because of slight fever, and received intravenous glucose infusion without any vitamins." | ( Kikuchi, S; Mochizuki, H; Moriya, A; Nakatani-Enomoto, S; Sugiura, Y; Ugawa, Y, 2010) |
| "Large variation in diabetic nephropathy prevalence remains and is associated with diabetes registry size, screening and treatment practices, suggesting that understanding this variation may help detect and better manage diabetic nephropathy." | ( Cardwell, CR; Fogarty, DG; Hunter, SJ; Kee, F; Magee, GM; Murphy, MC; Savage, G, 2010) |
| "On the other hand, treatment of diabetic nephropathy rats with metformin normalized all biochemical changes and the energy status in kidney tissues." | ( Alhaider, AA; Kfoury, H; Korashy, HM; Mansour, MA; Mobark, M; Sayed-Ahmed, MM, 2011) |
| "Forty-one patients with diabetic nephropathy with ESRD were enrolled and randomly assigned to the glucose group (GLU) treated with 8 L of 1." | ( Akagi, S; Inoue, J; Kojo, S; Makino, H; Morinaga, H; Nakao, K; Sugiyama, H; Takatori, Y; Wada, J, 2011) |
| "In PD therapy for diabetic nephropathy, the use of icodextrin-containing solutions has a beneficial effect on technique survival, but there are no apparent benefits or disadvantages in residual renal and peritoneal functions compared with conventional PD with glucose solution." | ( Akagi, S; Inoue, J; Kojo, S; Makino, H; Morinaga, H; Nakao, K; Sugiyama, H; Takatori, Y; Wada, J, 2011) |
| "rapamycin in the treatment of diabetic nephropathy, 8-week old diabetic (db/db) mice received everolimus (2 mg/kg every day) or rapamycin (2 mg/kg every day) for 4 weeks or 12 weeks respectively." | ( Chen, J; Cheng, L; Mao, X, 2011) |
| "The treatment of diabetic nephropathy near the beginning at microalbuminuria stage with angiotensin-II-AT1 receptor blockers (ARBs) improves blood pressure control and halts disease progression of diabetic nephropathy." | ( Balakumar, P; Bishnoi, HK; Mahadevan, N, 2012) |
| "Indices of diabetic nephropathy (DN) and oxidative stress were reduced by NDGA or pravastatin therapy with no statistical difference between the 2 lines of therapy." | ( Gad, HI, 2012) |
| "Progressive diabetic nephropathy showed vasoconstriction and a loss of blood flow in PTCs that was ameliorated by NaHS treatment." | ( Imai, E; Kimura, T; Kojima, H; Kosugi, T; Maruyama, S; Matsuo, S; Niki, I; Sato, W; Taniguchi, S; Yamamoto, J; Yamamoto, T; Yuzawa, Y, 2013) |
| "And they were divided into four groups: diabetic nephropathy (vehicle treatment), irbesartan (20 mg×kg(-1)×d(-1)), low-dosage XST (900 mg×kg(-1)×d(-1)) and high-dosage XST (1800 mg×kg(-1)×d(-1))." | ( Liang, H; Weng, JP; Xia, X; Xu, F; Yan, JH; Zhang, L; Zhao, Y; Zhu, YH, 2012) |
| "The need for an improved treatment for diabetic nephropathy is greatest in patients who do not adequately respond to angiotensin II receptor blockers (ARBs)." | ( Alter, ML; Henze, A; Hocher, B; Klein, T; Krause-Relle, K; Ott, IM; Raila, J; Sharkovska, Y; Tsuprykov, O; von Websky, K, 2012) |
| "Lumbrokinase treatment attenuated diabetic nephropathy in rats, possibly through increasing the activity of MMPs and the subsequent degradation of extracellular matrix." | ( Cheng, X; Ge, N; Li, S; Li, Y; Shao, M; Shen, J; Sun, H, 2013) |
| "The difficulty of diabetic nephropathy (DN) treatment makes prevention the best choice." | ( Cheng, YX; Lu, Q; Luo, J; Luo, Q; Wang, SM, 2013) |
| "In patients with diabetic nephropathy and hypertension, olmesartan significantly reduced proteinuria, independent of ACEI treatment and cardiovascular outcome but failed to show additional renal benefit compared with ACEI treatment alone." | ( Chan, JC; Haneda, M; Harada, A; Imai, E; Ito, S; Kobayashi, F; Makino, H; Yamasaki, T, 2013) |
| "A total of 45 type 2 diabetic kidney disease patients were enrolled into this prospective study, and were randomly divided into 3 groups: TwHF treatment group (DT, n = 15), irbesartan treatment group (DI, n = 15), and TwHF combined with irbesartan treatment group (DTI, n = 15)." | ( Ma, RX; Zhang, W; Zhao, N, 2013) |
| "Since current treatments for diabetic nephropathy do not prevent renal damage, we postulated an alternative treatment with boldine, an alkaloid obtained from boldo with antioxidant, anti-inflammatory, and hypoglycemic effects." | ( Arismendi, MN; Boric, MP; Hernández-Salinas, R; Sáez, JC; Velarde, V; Vielma, AZ, 2013) |
| "surgical therapy in obese adults with diabetic kidney disease exist, hence assessing the metabolic benefits vs." | ( Agrawal, V; Bhattacharya, A; Rao, BB, 2014) |
| "The results indicated the prevention of diabetic nephropathy in rats by OPE treatment and suggest OPE as a potential treatment option." | ( Addepalli, V; Parkar, N, 2014) |
| "Vitamin D3-treated patients with diabetic nephropathy had a statistically significant reduction in 24-hour proteinuria (weighted mean difference -0." | ( Dong, J; Liao, L; Shang, H; Wang, H; Zhang, D; Zhao, J, 2014) |
| "cassia bark on diabetic nephropathy which provided new evidences for the traditional use of this herb to treat diabetic nephropathy and associated kidney diseases." | ( Cheng, YX; Fang, P; Li, N; Lu, Q; Yan, YM; Yang, MT, 2015) |
| "Fifty-two Japanese patients with diabetic nephropathy and albuminuria (100 mg/gCr-2000 mg/gCr) treated with renin-angiotensin system (RAS) blockade were enrolled in a prospective, randomized, open-label study." | ( Ando, M; Araki, H; Goto, M; Imai, E; Kanasaki, K; Kato, S; Kobori, H; Koya, D; Makino, H; Maruyama, S; Matsuo, S; Nishiyama, A; Ogawa, D; Oiso, Y; Uzu, T; Wada, J, 2015) |
| "In the experiments, diabetic nephropathy rats were treated with berberine (0, 50, 100, 200 mg/kg) respectively." | ( Ding, HH; Ni, WJ; Qiu, YY; Tang, LQ; Zhou, H, 2015) |
| "To explore the role of APPL1 in diabetic nephropathy, we upregulated the expression of APPL1 in cultured mouse podocytes by adenovirus infection and tested the effects of APPL1 overexpression in podocytes treated with high glucose." | ( Hu, Z; Ji, Z; Xu, Y, 2015) |
| "Although diabetic nephropathy is associated with classic risk factors, early initiation of intensive treatment should be a priority in order to prevent worsening renal function." | ( Bonal, J; Bonet, J; Romero, R; Salinas, I; Sanmartí, A; Torres, F; Troya, MI, 2016) |
| "ICA II treatment could ameliorate diabetic nephropathy in STZ-induced diabetic rats by increasing endothelial cell contents, downregulating TGF-β/Smad/CTGF signaling pathway and oxidative stress level, and promoting cell proliferation both in kidney cortex and medulla." | ( Gao, Z; Guan, R; Lei, H; Li, H; Tian, W; Wang, L; Xin, Z; Xu, Y; Yang, B, 2015) |
| "In the early stage of diabetic nephropathy, paricalcitol treatment counterbalances the effect of diabetes on circulating ACE2 activity." | ( Anguiano, L; Clotet, S; Pascual, J; Rebull, M; Riera, M; Roca-Ho, H; Soler, MJ, 2016) |
| "After 6 weeks of treatment, diabetic nephropathy biomarkers were assessed." | ( Ahmed, RM; Al-Amin, MA; Al-Onazi, AS; Al-Rasheed, NM; Attia, HA; Poizat, C, 2016) |
| "Diabetes treatment in patients with diabetic kidney disease is challenging, in part because of progression of renal failure-related changes in insulin signaling, glucose transport and metabolism, favoring both hyperglycemic peaks and hypoglycemia." | ( Betônico, CC; Correa-Giannella, ML; Nery, M; Queiroz, M; Titan, SM, 2016) |
| "HKC was administered to the diabetic nephropathy rats at three different doses: high dose HKC (300mg/kg/d); middle dose HKC (175mg/kg/d); and low dose HKC (75mg/kg/d)." | ( Ge, J; Miao, JJ; Sun, XY; Yu, JY, 2016) |
| "He was a dialyzed patient due to diabetic nephropathy and was registered to prospective blood sampling for pharmacokinetics analysis during chemotherapy." | ( Funakoshi, T; Horimatsu, T; Matsubara, K; Matsubara, T; Miyamoto, S; Muto, M; Nakagawa, S; Nishikawa, Y; Yanagita, M; Yonezawa, A, 2017) |
| "K-877 administration ameliorates diabetic nephropathy, at least in part, via inhibition of renal lipid content and oxidative stress." | ( Inoguchi, T; Kimura, S; Maeda, Y; Maeno, S; Maki, T; Makimura, H; Sonoda, N; Takayanagi, R, 2017) |
| "Gliclazide treatment lessens diabetic nephropathy, probably partially by suppressing the GRP78- and sXBP1-mediated ER response." | ( Ren, X; Wang, X; Zhang, M; Zhang, YW, 2018) |
| "CV = cardiovascular DMN = diabetic nephropathy eGFR = estimated glomerular filtration rate fT4 = free thyroxine HbA1c = glycosylated hemoglobin HR = hazard ratio hs-CRP = high-sensitivity C-reactive protein LDL-C = low-density lipoprotein cholesterol SCH = subclinical hypothyroidism T2DM = type 2 diabetes THRT = thyroid hormone replacement therapy TSH = thyroid-stimulating hormone." | ( Cha, MU; Han, SH; Jhee, JH; Kang, SW; Kee, YK; Kim, H; Kim, S; Lee, M; Park, JT; Park, S; Seo, C; Yoo, TH; Yun, HR, 2018) |
| "Forty SD rats with diabetic nephropathy induced by intraperitoneal injection of 65 mg/kg streptozotocin were randomized equally into 5 groups, including a diabetic nephropathy model group and 4 treatment groups, with 8 normal SD rats as the normal control group." | ( Dong, P; Wang, YH; Wu, JJ; Zhang, M; Zhu, XN, 2018) |
| "Patients with diabetic nephropathy develop nephrotic syndrome and may show limited response to conventional therapy." | ( Hoshiyama, A; Kamata, Y; Masaki, T; Shichiri, M; Takada, T; Toki, T, 2018) |
| "The current treatment for diabetic nephropathy (DN) is still limited." | ( Chen, Y; Duan, Y; Han, J; Li, Q; Li, X; Liu, L; Liu, M; Ma, C; Qian, K; Wang, Y; Yang, J; Yang, S; Yang, X; Zhao, B; Zhu, Y, 2019) |
| "Treatment of diabetic nephropathy (DN) in an early stage can effectively inhibit its progression." | ( Abdel Ghafar, MT; Abo El Gheit, RE; Keshk, WA; Okda, HI; Shalaby, KH; Soliman, NA, 2020) |
| "More effective treatments for diabetic nephropathy remain a major unmet clinical need." | ( Benigni, A; Bolognini, S; Cassis, P; Corna, D; Locatelli, M; Novelli, R; Perico, L; Remuzzi, G; Villa, S; Zanchi, C; Zoja, C, 2020) |
| "A large number of patients with diabetic kidney disease (DKD) approach traditional Chinese medicine (TCM) owing to discontent with standard treatments." | ( Chen, K; Gan, W; Huang, Q; Liao, T; Tang, S; Xie, C; Zhang, C; Zhao, K, 2020) |
| "The incidence of diabetic nephropathy (DN) is increasing year by year, the pathogenesis is complicated, and renal fibrosis occurs during the progress of the disease, which is very difficult to treat." | ( Guo, J, 2021) |
| "Despite considerable investigation in diabetic nephropathy (DN) pathogenesis and possible treatments, current therapies still do not provide competent prevention from disease progression to end-stage renal disease (ESRD) in most patients." | ( Azarpira, N; Mostafavi-Pour, Z; Shahrokhi, SZ; Yarahmadi, A, 2021) |
| "Currently, drugs for the treatment of diabetic nephropathy (DN) are lacking." | ( Jing, M; Liu, Q; Zhang, L, 2021) |
| "We randomly assigned 40 patients with diabetic nephropathy and albuminuria 30-299 mg/day to treatment with carnosine (2 g/day) or placebo for 12 weeks." | ( Satirapoj, B; Siriwattanasit, N; Supasyndh, O, 2021) |
| "has been widely used for the therapy of diabetic nephropathy (DN) in traditional Chinese medicine (TCM)." | ( Fang, KL; Shen, T; Wang, T; Wang, XN; Xiang, L; Xu, LT; Zhang, K; Zhao, Y, 2021) |
| "The anti-diabetic nephropathy properties were systematically analyzed in the diabetic db/db mice treated with Met, BBR or with combination of Met and BBR." | ( Sun, G; Sun, X; Zhang, B; Zhang, C; Zhang, X, 2021) |
| "Diabetic nephropathy, included in diabetic kidney disease (DKD), is the primary disease leading to end-stage renal disease (ESRD) or dialysis treatment, accounting for more than 40% of all patients with ESRD or receiving dialysis." | ( Kitamoto, M; Konishi, N; Maekawa, M; Maekawa, T; Nakagawa, T; Ohta, T; Sasase, T; Takagi, K; Takeuchi, S; Toyoda, K; Yamada, T, 2022) |
| "In treating end-stage diabetic nephropathy patients, peritoneal dialysis had a lower incidence of cardiovascular and cerebrovascular events, as well as bleeding complication than hemodialysis." | ( Chen, M; Lan, L; Tian, L; Xie, J; Yan, Y; Zhang, Y; Zou, M, 2022) |
| "Given the challenges on diabetic nephropathy (DN) treatment, research has been carried out progressively focusing on dietary nutrition and natural products as a novel option with the objective of enhancing curative effect and avoiding adverse reactions." | ( Deng, H; Feng, X; Guo, X; Li, Q; Li, Z; Lu, C; Ma, X; Wang, J; Yan, S; Zeng, J; Zhao, Z, 2022) |
| "The attenuation of diabetic kidney disease (DKD) by metabolic surgery is enhanced by pharmacotherapy promoting renal fatty acid oxidation (FAO)." | ( Abdelaal, M; Abrahamsson, S; Brennan, EP; Chuah, YHD; Docherty, NG; Eckhardt, H; Elliott, JA; Fändriks, L; Fearon, N; Godson, C; Hutter, M; le Roux, CW; Malmodin, D; Martin, WP; Nair, M; Pedersen, A, 2022) |
| "The pathogenesis of diabetic nephropathy is multifactorial, and the development of an effective therapy remains to be elucidated." | ( Aboubaker, EM; Ali, FEM; Hofni, A; Ibrahim, ARN, 2023) |
| "Spontaneous type 2 diabetic nephropathy db/db mouse models were given three levels of lupenone (24 or 12 or 6 mg/kg/d) via intragastric administration for six weeks, and irbesartan treatment was used for the positive control group." | ( Huang, X; Kong, J; Li, X; Wang, X; Wu, H; Xu, F; Yang, X; Yu, P; Zhang, L; Zhen, C, 2023) |